Armando Santoro
#109,150
Most Influential Person Now
Researcher
Armando Santoro's AcademicInfluence.com Rankings
Armando Santorocomputer-science Degrees
Computer Science
#4070
World Rank
#4283
Historical Rank
Computational Linguistics
#319
World Rank
#324
Historical Rank
Machine Learning
#692
World Rank
#702
Historical Rank
Artificial Intelligence
#892
World Rank
#909
Historical Rank
Download Badge
Computer Science
Armando Santoro's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Armando Santoro Influential?
(Suggest an Edit or Addition)Armando Santoro's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Sorafenib in advanced hepatocellular carcinoma. (2008) (5771)
- Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. (2004) (3841)
- Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. (2006) (1169)
- Ceritinib in ALK-rearranged non-small-cell lung cancer. (2014) (875)
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. (2016) (729)
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. (2012) (707)
- Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. (2013) (524)
- Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. (2009) (523)
- Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. (2014) (513)
- Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. (1999) (512)
- Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. (1995) (496)
- SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. (2015) (481)
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial (2018) (462)
- Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. (2009) (446)
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib (2020) (433)
- Sorafenib: a review of its use in advanced hepatocellular carcinoma. (2009) (424)
- A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. (2009) (406)
- Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer (2012) (403)
- Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. (2017) (402)
- Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial (2019) (394)
- Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. (2016) (373)
- Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. (1987) (363)
- Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. (1986) (354)
- Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. (1985) (353)
- A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. (2001) (320)
- Second acute leukemia and other malignancies following treatment for Hodgkin's disease. (1986) (302)
- Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. (2005) (301)
- MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. (2009) (292)
- Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography. (2015) (276)
- EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. (2008) (268)
- Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. (2017) (263)
- Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. (2006) (259)
- Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. (2015) (254)
- Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. (2018) (249)
- A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. (2009) (245)
- Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. (1994) (244)
- Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. (2015) (238)
- Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. (1982) (236)
- Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. (2012) (234)
- Reduced Likelihood of Metastases in Patients with Microsatellite-Unstable Colorectal Cancer (2007) (233)
- Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. (2000) (233)
- CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. (2009) (227)
- Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. (2018) (227)
- Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. (1987) (226)
- Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. (2013) (215)
- Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. (2007) (213)
- Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. (2008) (211)
- Lung cancer screening with spiral CT: baseline results of the randomized DANTE trial. (2008) (207)
- Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer (2004) (207)
- Alternating drug combinations in the treatment of advanced Hodgkin's disease. (1982) (200)
- Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. (2017) (198)
- Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. (2012) (196)
- Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program (2008) (196)
- Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. (2019) (187)
- Second malignancies in Hodgkin's disease: a complication of certain forms of treatment. (1980) (186)
- Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. (2018) (183)
- Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. (2016) (183)
- Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients (2008) (179)
- Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma (2017) (179)
- Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. (2005) (164)
- An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. (2008) (163)
- Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. (2008) (159)
- Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. (2020) (158)
- Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients (2015) (157)
- Drugs ten years later: epirubicin. (1993) (155)
- Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. (2013) (152)
- The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial (2009) (148)
- Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment (2014) (146)
- Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis (2017) (146)
- The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies (2005) (137)
- Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. (1987) (136)
- Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. (2014) (135)
- Absence of treatment-induced second neoplasms after ABVD in Hodgkin's disease. (1982) (134)
- High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. (1996) (133)
- The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. (2013) (129)
- Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. (1999) (127)
- Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial (2009) (123)
- Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. (2015) (121)
- Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. (2011) (120)
- Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer (2015) (120)
- Cyvadic in advanced soft tissue sarcoma: A randomized study comparing two schedules: A study of the EORTC soft tissue and bone sarcoma group (1984) (120)
- Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery (2016) (119)
- BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. (2011) (115)
- First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. (2008) (114)
- ABVD chemotherapy in the treatment of Hodgkin's disease. (1982) (114)
- Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma. (2012) (111)
- PD-1 Blockade in Anaplastic Thyroid Carcinoma (2020) (110)
- Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. (2014) (110)
- Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials (2008) (110)
- Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin’s lymphoma responding to prior salvage therapy (2012) (110)
- Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. (2016) (110)
- Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. (2010) (108)
- Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). (2003) (108)
- Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy? (2003) (107)
- Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. (2011) (107)
- Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose (2006) (105)
- Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study (2016) (104)
- Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer. (2010) (104)
- Advances in the biology of malignant pleural mesothelioma. (2011) (103)
- Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) (2009) (103)
- Olfactory system of highly trained dogs detects prostate cancer in urine samples. (2015) (102)
- Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. (2021) (101)
- Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience (2017) (100)
- A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. (2015) (98)
- Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. (2008) (98)
- Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine. (1999) (96)
- Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. (2020) (95)
- Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. (2013) (95)
- Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study. (2016) (94)
- Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. (2006) (94)
- Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. (2014) (94)
- Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer (2020) (93)
- Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma (2013) (92)
- Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach (2014) (90)
- Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin (2011) (90)
- Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma. (1993) (90)
- Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma (2008) (87)
- Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (2020) (87)
- Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study (2020) (85)
- Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease. (1994) (84)
- Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments (2012) (83)
- An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers (2016) (83)
- Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status. (2019) (83)
- Clinical outcome of hypofractionated stereotactic radiotherapy for abdominal lymph node metastases. (2011) (81)
- KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study (2019) (80)
- Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study. (2016) (80)
- Combined modality treatment for primary gastrointestinal non-Hodgkin's lymphoma: the Milan Cancer Institute experience. (1993) (79)
- Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study (2019) (79)
- Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. (2021) (79)
- In vitro anti‐tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5 (1993) (77)
- Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy. (2010) (77)
- EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer (2007) (77)
- Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience. (1991) (76)
- CheckMate 040 Cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. (2021) (76)
- CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease. (1986) (75)
- Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials (2013) (75)
- PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy (2019) (74)
- Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. (2010) (74)
- A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis (2013) (73)
- Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial. (2014) (73)
- Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma (2019) (73)
- Volumetric modulation arc radiotherapy compared with static gantry intensity-modulated radiotherapy for malignant pleural mesothelioma tumor: a feasibility study. (2010) (72)
- Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors (2021) (70)
- Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. (2007) (70)
- Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. (2018) (69)
- Increased SOX2 Gene Copy Number Is Associated with FGFR1 and PIK3CA Gene Gain in Non-Small Cell Lung Cancer and Predicts Improved Survival in Early Stage Disease (2014) (69)
- Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. (2012) (69)
- Second-line treatment for malignant pleural mesothelioma. (2010) (68)
- Clinicopathological and Immunohistochemical Characteristics in Male Breast Cancer: A Retrospective Case Series. (2015) (68)
- Randomized phase II study of danusertib in patients with metastatic castration‐resistant prostate cancer after docetaxel failure (2013) (68)
- MicroRNA‐425‐3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma (2015) (68)
- Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? (2008) (67)
- Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma. (2015) (67)
- Preclinical assessment of volumetric modulated arc therapy for total marrow irradiation. (2011) (66)
- Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in Non–Small Cell Lung Cancer Patients Treated with Gefitinib (2010) (66)
- Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes (2021) (66)
- Classical Hodgkin’s lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up (2009) (66)
- High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study. (2002) (63)
- How I treat: diagnosing and managing "in situ" lymphoma. (2011) (63)
- 126 Evaluation of topotecan (Hycamtin™) in relapsed small cell lung cancer (SCLC). A multicentre phase II study (1997) (62)
- Salvage chemotherapy in Hodgkin's disease. Results in patients relapsing more than twelve months after first complete remission. (1990) (62)
- Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. (2010) (59)
- Retroperitoneal Sarcoma: Is It Time to Change the Surgical Policy? (2011) (59)
- Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. (1993) (59)
- Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP. (1986) (56)
- Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease. (1997) (56)
- Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib (2016) (56)
- Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. (2011) (56)
- Expression and Mutational Status of c-kit in Thymic Epithelial Tumors (2010) (54)
- Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. (2014) (53)
- Insulin‐like growth factor‐1 receptor and phosphorylated AKT‐serine 473 expression in 132 resected thymomas and thymic carcinomas (2010) (53)
- Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy. (2013) (53)
- Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. (2006) (53)
- Assessment of tumor response in malignant pleural mesothelioma. (2007) (53)
- Ten‐year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus (2002) (52)
- Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. (2015) (52)
- Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy. (2003) (52)
- Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530 (2018) (52)
- Multidisciplinary treatment of malignant pleural mesothelioma. (2007) (51)
- Stereotactic body radiation therapy: A promising chance for oligometastatic breast cancer. (2016) (50)
- The early expansion of anergic NKG2Apos/CD56dim/CD16neg natural killer represents a therapeutic target in haploidentical hematopoietic stem cell transplantation (2018) (49)
- A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. (2008) (49)
- Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. (2014) (49)
- Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors (2014) (49)
- Carminomycin vs adriamycin in advanced soft tissue sarcomas: an EORTC randomised phase II study. (1983) (48)
- Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study. (2002) (48)
- Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open‐label trial (2017) (47)
- Clinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic Patients. (2016) (46)
- Abstract CT103: Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: Preliminary results from KEYNOTE-028 (2015) (45)
- Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study (2011) (45)
- Magnetic resonance imaging in the initial staging of Hodgkin's disease and non-Hodgkin lymphoma. (1991) (45)
- Third-line salvage chemotherapy in Hodgkin's disease. (1985) (45)
- Initial chemotherapy for primary resectable large-cell lymphoma of the stomach. (1997) (44)
- Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study (2016) (44)
- Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma (2017) (44)
- Gonadal damage in Hodgkin's disease from cancer chemotherapeutic regimens. (1984) (44)
- Massive chemotherapy with non-frozen autologous bone marrow transplantation in 13 cases of refractory Hodgkin's disease. (1985) (44)
- A phase 2 study of a novel transforming growth factor-beta (TGF-{beta}1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC). (2014) (44)
- Cancer patients and survivors: changing words or changing culture? (2013) (44)
- Predictive value of early 18F‐fluorodeoxyglucose positron emission tomography (FDG‐PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high‐dose chemotherapy (2009) (44)
- Alternating versus hybrid MOPP-ABVD in Hodgkin's disease: the Milan experience. (1991) (44)
- Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma (2016) (43)
- Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: rationale, background studies, and recent results. (1982) (43)
- Search: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients with Hepatocellular Carcinoma (HCC) (2012) (43)
- Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin (2011) (43)
- Combined regimen of cisplatin, doxorubicin, and α‐2b interferon in the treatment of advanced malignant pleural mesothelioma (2001) (43)
- The “old drug” dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas (2008) (43)
- Percutaneous vertebral augmentation in metastatic disease: state of the art. (2011) (43)
- Characterisation of the immune-related transcriptome in resected biliary tract cancers (2017) (42)
- ATIM-35. RESULTS OF THE PHASE IB KEYNOTE-028 MULTI-COHORT TRIAL OF PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT PD-L1-POSITIVE GLIOBLASTOMA MULTIFORME (GBM) (2016) (42)
- Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy. (2010) (41)
- 1293PEVALUATION OF CERITINIB-TREATED PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES IN THE ASCEND-1 STUDY. (2014) (41)
- T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors. (2017) (41)
- Early Surgical Experience with Minimally Invasive Percutaneous Approach for Patients with Metastatic Epidural Spinal Cord Compression (MESCC) to Poor Prognoses (2011) (41)
- Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer. (2004) (40)
- Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): Results of the METIV-HCC phase III trial. (2017) (40)
- Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study. (2000) (40)
- Prognostic and predictive value of MET deregulation in non-small cell lung cancer. (2015) (40)
- EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib. (2014) (40)
- Assessment of prognostic factors in patients with metastatic epidural spinal cord compression (MESCC) from solid tumor after surgery plus radiotherapy: a single institution experience (2012) (40)
- First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors. (2012) (39)
- Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II (2015) (39)
- Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry. (2021) (39)
- Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. (2015) (39)
- Early clinical experience with volumetric modulated arc therapy in head and neck cancer patients (2010) (39)
- Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. (2014) (39)
- Prognosis of bulky Hodgkin's disease treated with chemotherapy alone or combined with radiotherapy. (1985) (39)
- Avadomide monotherapy in relapsed/refractory DLBCL: Safety, efficacy, and a predictive gene classifier. (2020) (39)
- [Breast cancer in the early stage]. (2012) (39)
- A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma. (2013) (38)
- Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top". (2018) (38)
- High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid. (2009) (38)
- Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma (2015) (37)
- Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma. (2014) (37)
- AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients (2016) (37)
- Lung cancer screening with low-dose spiral computed tomography: evidence from a pooled analysis of two Italian randomized trials (2017) (36)
- Are interleukin-16 and thrombopoietin new tools for the in vitro generation of dendritic cells? (2004) (36)
- Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease. (1999) (36)
- Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma (2013) (36)
- Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient's follow-up. (2008) (36)
- Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition. (2019) (36)
- Metastasis of Hepatocellular Carcinoma to the Heart: A Case Report and Review of the Literature (2004) (36)
- Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: Results of a randomized controlled phase II trial (RCT). (2012) (35)
- The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo (2013) (35)
- Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come (2017) (35)
- Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery? (2018) (35)
- Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer (2011) (34)
- Re-irradiation of metastatic spinal cord compression: a feasibility study by volumetric-modulated arc radiotherapy for in-field recurrence creating a dosimetric hole on the central canal. (2010) (34)
- Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib (2020) (34)
- Controversies in clinicopathological characteristics and treatment strategies of male breast cancer: A review of the literature. (2017) (34)
- Primary refractory and early‐relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment (2015) (34)
- Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases (2013) (34)
- 1295PEFFICACY AND SAFETY OF CERITINIB IN PATIENTS (PTS) WITH ADVANCED ANAPLASTIC LYMPHOMA KINASE (ALK)-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC): AN UPDATE OF ASCEND-1. (2014) (34)
- Large volume unresectable locally advanced non-small cell lung cancer: acute toxicity and initial outcome results with rapid arc (2010) (33)
- Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi (2014) (33)
- Evidence of altered autonomic cardiac regulation in breast cancer survivors (2015) (33)
- Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies (2015) (33)
- Lung resection for metastatic sarcomas: Total survival from primary treatment (1989) (33)
- KRAS mutation in lung metastases from colorectal cancer: prognostic implications (2015) (32)
- Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) (2004) (32)
- The role of inflammation in lymphoma. (2014) (32)
- Complications of therapy and a diagnostic dilemma case. Case 2. Cutaneous toxicity induced by cetuximab. (2003) (31)
- Dose-escalation of CHOP in non-Hodgkin's lymphoma. (1999) (31)
- Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP). (2001) (31)
- Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy. (2007) (31)
- Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications (2018) (31)
- Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer. (2012) (31)
- Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics (2010) (31)
- Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study. (2008) (31)
- Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma. (2016) (31)
- Efficacy Analysis for Molecular Subgroups in MARQUEE: a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial of Tivantinib (ARQ 197) Plus Erlotinib versus Placebo plus Erlotinib in Previously Treated Patients with Locally Advanced or Metastatic, Non-squamous, Non-small Cell Lung Cancer (NSCLC (2014) (31)
- Value of Surgical Resection in Patients with Newly Diagnosed Grade III Glioma Treated in a Multimodal Approach: Surgery, Chemotherapy and Radiotherapy (2016) (31)
- Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial (2016) (31)
- Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers. (2015) (30)
- Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide. (2002) (30)
- Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications. (1998) (30)
- Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma (2021) (30)
- Comprehensive geriatric evaluation in elderly patients with lymphoma: feasibility of a patient-tailored treatment plan. (2003) (30)
- Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group. (2012) (30)
- Irinotecan and raltitrexed: an active combination in advanced colorectal cancer. (2002) (30)
- Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY). (2013) (30)
- A prospective study on survival in cancer patients with and without venous thromboembolism (2013) (29)
- Donor-Specific Anti-HLA Antibodies in Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: Risk of Graft Failure, Poor Graft Function, and Impact on Outcomes. (2019) (29)
- Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma (2015) (29)
- Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma (2010) (29)
- Modulation of Biliary Cancer Chemo‐Resistance Through MicroRNA‐Mediated Rewiring of the Expansion of CD133+ Cells (2019) (28)
- Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Non–Small-Cell Lung Cancer (2015) (28)
- Prophylaxis of central venous catheter‐related thrombosis with minidose warfarin in patients treated with high‐dose chemotherapy and peripheral‐blood stem‐cell transplantation: Retrospective analysis of 228 cancer patients (2006) (28)
- Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040. (2021) (28)
- Rectal squamous cell carcinoma treated with chemoradiotherapy: report of six cases (2010) (28)
- Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphoma. (2009) (28)
- Low Incidence of SARS-CoV-2 in Patients with Solid Tumours on Active Treatment: An Observational Study at a Tertiary Cancer Centre in Lombardy, Italy (2020) (28)
- Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study (2021) (28)
- Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. (2021) (28)
- Regorafenib for the treatment of unresectable hepatocellular carcinoma (2017) (27)
- In situ follicular lymphoma: pathologic characteristics and diagnostic features (2012) (27)
- Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma. (2016) (27)
- The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer (2018) (27)
- KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL). (2020) (27)
- Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study. (2016) (26)
- Early stage Hodgkin's disease: ten-year results of a non-randomised study with radiotherapy alone or combined with MOPP. (1992) (26)
- Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study. (2020) (26)
- Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Pooled results from the KEYNOTE-028 and KEYNOTE-158 studies. (2020) (26)
- Abstract CT183: Phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies (2019) (26)
- Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. (2021) (26)
- Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial (2019) (26)
- Tandem high‐dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: A monocenter prospective study (2007) (26)
- Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer (2009) (25)
- Dimension of Residual CT Scan Mass in Hodgkin's Lymphoma (HL) Is a Negative Prognostic Factor in Patients with PET Negative After Chemo+/− Radiotherapy (2011) (25)
- Prostatic stromal tumor with fatal outcome in a young man: histopathological and immunohistochemical case presentation (2010) (25)
- European Experience of Adjuvant Chemotherapy for Soft Tissue Sarcoma: Interim Report of a Randomized Trial of Cyvadic Versus Control (1988) (25)
- Vertebroplasty for pain relief and spinal stabilization in multiple myeloma (2010) (25)
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to ECOG performance status: A subanalysis from the SHARP trial (2008) (25)
- Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial (2016) (25)
- Rapsody: randomized prospective phase II trial of two schedules of sorafenib daily and interferon-α 2A (IFN) in metastatic renal cell carcinoma (MRCC). GOIRC study 0681 (2007) (25)
- Anatomy driven optimization strategy for total marrow irradiation with a volumetric modulated arc therapy technique (2012) (25)
- Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma. (2016) (25)
- The present and the future landscape of treatment of advanced hepatocellular carcinoma. (2010) (24)
- Reduced‐intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high‐dose chemotherapy and autologous stem cell infusion (2007) (24)
- Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. (2020) (24)
- Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer (2009) (24)
- Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. (2014) (24)
- Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib. (2011) (24)
- Phase II, randomized trial of preoperative epirubicin-paclitaxel +/− gefitinib with biomarker evaluation in operable breast cancer (2008) (24)
- A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. (2014) (24)
- A phase 2 study of galunisertib, a novel transforming growth factor-beta (TGF-β) receptor I kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP). (2016) (24)
- Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases (2019) (24)
- Results of a First-In-Human Phase I Study of the Alk Inhibitor LDK378 in Advanced Solid Tumors (2012) (23)
- Improved 5-year survival in advanced Hodgkin's disease by combined modality approach (1979) (23)
- Results of salvage surgery for metastatic sarcomas. (1990) (23)
- Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) after Treatment with Nivolumab for Relapsed/Refractory Hodgkin Lymphoma (2016) (23)
- Outcome Evaluation of Oligometastatic Patients Treated with Surgical Resection Followed by Hypofractionated Stereotactic Radiosurgery (HSRS) on the Tumor Bed, for Single, Large Brain Metastases (2016) (23)
- BM-32CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL (2014) (23)
- Oral ulcer as an exclusive sign of gastric cancer: report of a rare case (2005) (23)
- Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040. (2020) (23)
- The patient’s CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide (2016) (23)
- Role of Computed Tomographyand [18F] Fluorodeoxyglucose Positron Emission Tomography Image Fusion in Conformal Radiotherapy of Non-Small Cell Lung Cancer: A Comparison with Standard Techniques with and without Elective Nodal Irradiation (2007) (23)
- Randomized phase III trial comparing infused 5-fluorouracil/folinic acid (LV5FU) versus LV5FU+irinotecan (LV5FU+IRI) as adjuvant treatment after complete resection of liver metastases from colorectal cancer (LMCRC). (CPT-GMA-301) (2008) (22)
- Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-α2a (IFN) in metastatic renal cell carcinoma (RAPSODY): GOIRC Study 0681 (2007) (22)
- Future developments in the management of malignant pleural mesothelioma (2009) (22)
- Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma (2017) (22)
- Evolution in the treatment strategy of Hodgkin's disease. (1982) (22)
- Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. (1990) (22)
- Multimodal approach to the management of metastatic epidural spinal cord compression (MESCC) due to solid tumors. (2010) (22)
- Survival Outcome and Prognostic Factors After Pulmonary Metastasectomy in Sarcoma Patients: A 18-Year Experience at a Single High-volume Referral Center (2019) (21)
- Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score (2021) (21)
- Bendamustine combined with donor lymphocytes infusion in Hodgkin's lymphoma relapsing after allogeneic hematopoietic stem cell transplantation. (2014) (21)
- Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma (2015) (21)
- Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma. (2020) (21)
- Platinum salts in the treatment of BRCA-associated breast cancer: A true targeted chemotherapy? (2019) (21)
- Refining sorafenib therapy: lessons from clinical practice. (2015) (21)
- Lung Resection as Salvage Treatment for Metastatic Osteosarcoma (1988) (21)
- Chemotherapy in the multidisciplinary approach to soft tissue sarcomas. EORTC Soft Tissue and Bone Sarcoma Group studies in perspective. (1992) (21)
- Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases (2018) (21)
- O-082 A randomized phase III trial comparing ionafarnib/carboplatin/paclitaxel versus carboplatin/paclitaxel (CP) in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC) (2005) (21)
- Cabozantinib for the treatment of hepatocellular carcinoma (2019) (21)
- VP-16 in advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma group. (1987) (21)
- Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy (2019) (21)
- New reciprocal translocation t(5;10)(q33;q22) associated with atypical chronic myeloid leukemia. (1999) (21)
- Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma. (1996) (21)
- CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer (2012) (21)
- Phase II study of mitozolomide in advanced soft tissue sarcoma of adults: the EORTC Soft Tissue and Bone Sarcoma Group. (1992) (21)
- Combined Epirubicin and Interleukin-2 Regimen in the Treatment of Malignant Mesothelioma: A Multicenter Phase II Study of the Italian Group on Rare Tumors (1998) (20)
- Primary Malignant Neoplasms Associated with Chronic Lymphocytic Leukemia (1980) (20)
- BONE-MARROW PATTERNS AND CLINICAL STAGING IN CHRONIC LYMPHOCYTIC LEUKÆMIA (1978) (20)
- Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically (2012) (20)
- The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art. (2020) (20)
- IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients (2007) (20)
- Postmastectomy radiation therapy using VMAT technique for breast cancer patients with expander reconstruction (2019) (20)
- 502 Pembrolizumab (MK-3475) for patients (pts) with advanced colorectal carcinoma (CRC): Preliminary results from KEYNOTE-028 (2015) (20)
- Advanced soft tissue sarcoma: how many more trials with anthracyclines and ifosfamide? (1999) (20)
- Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis (2020) (20)
- Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma (2011) (20)
- Treatment strategies for Hodgkin's disease. (1988) (20)
- Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO) (2017) (20)
- Mobilization and collection of PBSC in healthy donors: comparison between two schemes of rhG‐CSF administration (1996) (20)
- Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment (2018) (19)
- Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK+) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1 (2014) (19)
- High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation for the treatment of solid tumors in adults: a critical review. (2007) (19)
- A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice (2013) (19)
- Thymoma Associated with Myasthenia and Autonomic anti-Hu Paraneoplastic Neuropathy (2009) (19)
- Herpes Infections in Breast Cancer Patients Treated with Adjuvant Chemotherapy (2007) (19)
- Third-line chemotherapy with CCNU, etoposide and prednimustine (CEP) in Hodgkin's disease (HD) resistant to MOPP and ABVD (1982) (19)
- Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors. (2011) (18)
- Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation (2016) (18)
- Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma (2017) (18)
- Retroperitoneal Sarcoma: Is It Time to Change the Surgical Policy? (2011) (18)
- Thyroid, pulmonary, and cardiac sequelae after treatment for Hodgkin's disease. (1992) (18)
- Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. (2013) (18)
- Hodgkin's disease: the Milan Cancer Institute experience with MOPP and ABVD. (1989) (18)
- NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW‐UP OF THE PHASE 2 CHECKMATE 205 TRIAL (2017) (18)
- Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. (2014) (17)
- Clinical management of peripherally inserted central catheters compared to conventional central venous catheters in patients with hematological malignancies: A large multicenter study of the REL GROUP (Rete Ematologica Lombarda ‐ Lombardy Hematologic Network, Italy) (2017) (17)
- European experience of adjuvant chemotherapy for soft tissue sarcoma: Preliminary report of randomized trial of cyclophosphamide, vincristine, doxorubicin, and dacarbazine (1985) (17)
- Infertility risk and teratogenicity of molecularly targeted anticancer therapy: A challenging issue. (2016) (17)
- Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma. (2013) (17)
- Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. (2022) (17)
- Impact of active cancer on COVID-19 survival: a matched-analysis on 557 consecutive patients at an Academic Hospital in Lombardy, Italy (2021) (17)
- Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study (2016) (17)
- NGR‐hTNF and Doxorubicin as Second‐Line Treatment of Patients with Small Cell Lung Cancer (2018) (17)
- Feasibility and toxicity of high‐dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non‐Hodgkin's lymphoma: Survey from a single institution (2003) (16)
- Topotecan (Hycamtin™) in small cell lung cancer (SCLC) after failure of first line therapy: Multicentre phase II study (1997) (16)
- Preliminary Studies on Melatonin in the Treatment of Myelodysplastic Syndromes Following Cancer Chemotherapy (1990) (16)
- Fatal infusion reaction to cetuximab: the need for predictive risk factors and safer patient selection. (2011) (16)
- Unsupervised versus Supervised Identification of Prognostic Factors in Patients with Localized Retroperitoneal Sarcoma: A Data Clustering and Mahalanobis Distance Approach (2018) (16)
- Prognostic and predictive role of [18F]fluorodeoxyglucose positron emission tomography (FDG‐PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up‐front pemetrexed‐based chemotherapy (2017) (16)
- Non-pegylated liposomal doxorubicin plus ifosfamide in metastatic soft tissue sarcoma: results from a phase-II trial. (2015) (16)
- 6576 POSTER Phase II Safety Study of the Oral Multikinase Inhibitor Regorafenib (BAY 73-4506) as Second-line Therapy in Patients With Hepatocellular Carcinoma (2011) (16)
- A double-blind placebo-controlled randomized study on the efficacy and safety of enoxaparin for the prevention of upper limb deep vein thrombosis in cancer patients with central vein catheter (2004) (16)
- Clinical relevance of clonal hematopoiesis in the oldest-old population. (2021) (16)
- Current Role of Autologous and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma (2015) (16)
- Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi (2016) (16)
- Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. (2020) (16)
- Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study. (2012) (16)
- Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)--A phase 2 study. (2016) (16)
- 42 Phase II study of BAY 43-9006 in patients with advanced hepatocellular carcinoma (HCC) (2004) (15)
- Anatomic location of breast cancer micrometastasis in sentinel lymph node predicts axillary status. (2006) (15)
- Comparative trial of BBR 2778 (pixantrone) + rituximab vs single agent rituximab in the treatment of relapsed/refractory indolent non-Hodgkin's lymphoma (NHL). (2006) (15)
- Evaluation of semen and pituitary gonadotropin function in men with untreated Hodgkin's disease. (1985) (15)
- Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study (2014) (15)
- Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma. (2021) (15)
- Mitomycin C (MCC) in advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. (1985) (15)
- Randomized phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis by tumor epidermal growth factor receptor (EGFR) staining. (2010) (15)
- Fulvestrant for advanced male breast cancer patients: a case series. (2011) (14)
- CLASSIFICATION OF LEUKEMIAS AND HEMATOSARCOMAS BASED ON CELL MEMBRANE MARKERS AND SCANNING ELECTRON MICROSCOPY (1976) (14)
- Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas (2004) (14)
- Cytogenetic study in therapy-related myelodysplastic syndromes (t-MDS) and acute non-lymphocytic leukaemia (t-ANLL). (1990) (14)
- Increasing dose of Continuous Infusion Ifosfamide and Fixed dose of Bolus Epirubicin in Soft Tissue Sarcomas. A Study of the Italian Group on Rare Tumors (1999) (14)
- Predictive Factors of Eribulin Activity in Metastatic Breast Cancer Patients (2018) (14)
- Impact of Exon 19 Deletion Subtypes in EGFR‐Mutant Metastatic Non–Small‐Cell Lung Cancer Treated With First‐Line Tyrosine Kinase Inhibitors (2019) (14)
- Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET—Letter (2013) (14)
- Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single‐Center, Observational Study (2018) (14)
- Hypofractionation with simultaneous boost in breast cancer patients receiving adjuvant chemotherapy: A prospective evaluation of a case series and review of the literature. (2018) (14)
- Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer (2021) (14)
- Sorafenib is active on lung metastases from synovial sarcoma. (2008) (14)
- OA13.03 Long-Term Overall Survival for Patients with Malignant Pleural Mesothelioma on Pembrolizumab Enrolled in KEYNOTE-028 (2017) (14)
- Surgery Followed by Radiotherapy for the Treatment of Metastatic Epidural Spinal Cord Compression From Breast Cancer (2011) (14)
- Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. (2018) (14)
- Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper. (2015) (14)
- Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study (2018) (13)
- Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor? (2006) (13)
- Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors. (2013) (13)
- Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study (2005) (13)
- Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study (2018) (13)
- Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas. (1993) (13)
- Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patients' management: Close to the clinic? (2020) (13)
- Unexpected Low Efficacy of Stealth Liposomal Doxorubicin (Caelyx) and Vinorelbine in Metastatic Breast Cancer (2004) (13)
- Trabectedin for the treatment of soft tissue sarcomas (2016) (13)
- Peripheral Blood Stem Cells versus Bone Marrow for T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma. (2019) (13)
- Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. (2017) (13)
- Thrombin generation predicts early recurrence in breast cancer patients (2020) (13)
- A Molecular Model for the Prediction of Progression Free Survival in Young Mantle Cell Lymphoma Patients Treated with Cytarabine-Based High Dose Sequential Chemotherapy and Autologous Stem Cell Transplantation: Results from the MCL0208 Phase III Trial from Fondazione Italiana Linfomi (FIL) (2015) (13)
- Desensitization with plasma exchange in a patient with human leukocyte antigen donor‐specific antibodies before T‐cell–replete haploidentical transplantation (2016) (13)
- A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma (2018) (13)
- Prophylaxis of central venous catheter-related thrombosis with minidose warfarin: analysis of its use in 427 cancer patients. (2005) (12)
- Intra-arterial induction chemotherapy for soft tissue sarcomas. (1992) (12)
- The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study (2007) (12)
- Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin’s lymphoma. Assessment of risk of toxicity and secondary cancer induction (2020) (12)
- Imatinib mesylate in desmoplastic small round cell tumors. (2017) (12)
- Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. (2017) (12)
- Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer (2019) (12)
- Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives (2021) (12)
- Insights for the application of TILs and AR in the treatment of TNBC in routine clinical practice (2020) (12)
- Vertebral metastases reirradiation with volumetric-modulated arc radiotherapy. (2012) (12)
- Level of HER2/neu amplification in primary tumours and metastases in HER2-positive breast cancer and survival after trastuzumab therapy. (2013) (12)
- Beyond semantics: the need to better categorize patients with cancer. (2013) (12)
- High‐dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas (1993) (12)
- Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas. (2006) (12)
- Chemotherapy with Mitomycin C and Capecitabine in Patients with Advanced Colorectal Cancer Pretreated with Irinotecan and Oxaliplatin (2006) (12)
- Clinical Classification and Survival in Chronic Lymphocytic Leukemia (1979) (12)
- Metiv-HCC: A phase III clinical trial evaluating tivantinib (ARQ 197), a MET inhibitor, versus placebo as second-line in patients (pts) with MET-high inoperable hepatocellular carcinoma (HCC). (2013) (12)
- Multimodality imaging of adult rhabdomyosarcoma: the added value of hybrid imaging. (2020) (11)
- Neutrophil and lymphocyte blood count as potential predictive indicators of nivolumab efficacy in metastatic non-small-cell lung cancer. (2020) (11)
- Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) NSCLC: Subgroup analysis of the ASCEND-1 trial. (2014) (11)
- Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma (2018) (11)
- Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. (2021) (11)
- MOPP vs MOPP plus ABVD in stage IV Hodgkin's disease (1977) (11)
- Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors (2021) (11)
- Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma (2017) (11)
- Impact on Survival of Timing and Duration of Adjuvant Chemotherapy in Radically Resected Gastric Cancer (2016) (11)
- A multistep randomized phase II/III trial comparing oxaliplatin (OXA)+5 fluorouracil (FU) to vinorelbine (VIN)+FU (FUN) after taxane (T)/anthracycline (A) failure in advanced/metastatic breast cancer (MBC) patients (pts): Final results. (2004) (11)
- Intramedullary astrocytoma with granular cell differentiation (2007) (11)
- Erratum: In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5 (Int. J. Cancer, 54, 8-15 (1993)) (1993) (11)
- EXTEND PIX301: a phase III randomized trial of pixantrone versus other chemotherapeutic agents as third-line monotherapy in patients with relapsed, aggressive non-Hodgkin's lymphoma. (2006) (11)
- Abstract CT171: Phase I study of BLZ945 alone and with spartalizumab (PDR001) in patients (pts) with advanced solid tumors (2020) (11)
- Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation (2003) (11)
- NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY (2021) (11)
- Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer. (2012) (11)
- Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer (2022) (11)
- Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial. (2019) (11)
- Low-dose “metronomic chemotherapy” with oral cyclophosphamide and methotrexate in metastatic breast cancer: a case report of extraordinarily prolonged clinical benefit (2012) (10)
- COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry (2022) (10)
- Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide (2019) (10)
- Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas (2002) (10)
- Tivantinib for hepatocellular carcinoma (2015) (10)
- Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma (2017) (10)
- Extended-field radiotherapy in favorable stage IA-IIA Hodgkin's disease (prognostic role of stage). (1994) (10)
- Neutropenic Enterocolitis: Is There Aright Timing for Surgery? Assessment of a Clinical Case (2007) (10)
- Current Perspectives on Immunotherapy in the Peri-Operative Setting of Muscle-Infiltrating Bladder Cancer (2020) (10)
- High dose cyclophosphamide: stem cell mobilizing capacity in 21 patients. (1994) (10)
- Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study. (2017) (10)
- Epirubicin plus ifosfamide and dacarbazine (EID) in advanced soft tissue sarcomas. (1992) (10)
- CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) By Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects with Relapsed or Refractory Non-Hodgkin’s Lymphoma and Multiple Myeloma (2014) (10)
- Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: when, why and what? (2021) (10)
- ARQ 197-215: A randomized, placebo-controlled phase II clinical trial evaluating the c-Met inhibitor, ARQ 197, in patients (pts) with hepatocellular carcinoma (HCC). (2010) (10)
- Chapter 16 Detection of SCLC metastic cells in bone marrow by means of the monoclonal antibody MLuC1 (1988) (10)
- Outcome Evaluation of HER2 Breast Cancer Patients with Limited Brain Metastasis. (2017) (10)
- Abstract B057: BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors (2019) (10)
- Idiopathic Thrombocytopenic Purpura and Splenic Marginal-zone B-cell Lymphoma: A Casual Correlation? (2003) (9)
- Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity? (2018) (9)
- Single-cell profiling identifies impaired adaptive NK cells expanded after HCMV reactivation in haploidentical HSCT (2021) (9)
- Efficacy, safety, tolerability, and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase II SHELTER study. (2012) (9)
- The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer. (2013) (9)
- Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients (2020) (9)
- 11C-labeled methionine and evaluation of malignant pleural mesothelioma. (2007) (9)
- Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study (2019) (9)
- Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma. (2011) (9)
- FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study. (2015) (9)
- Salvage Treatment with Lenalidomide and Dexamethasone In Patients with Relapsed Refractory Mantle Cell Lymphoma: Clinical Results and Modifications of Angiogenic Biomarkers (2010) (9)
- Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: Clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors (2011) (9)
- Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial (2019) (9)
- Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis (2018) (9)
- Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer (2022) (9)
- New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma. (2010) (9)
- Superiority of three-week vs. four-week schedule of cisplatin (CDDP) and gemcitabine (GEM): Results of a randomized phase II study (2000) (9)
- Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1–2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial (2022) (9)
- Development of an immobilization device for Total Marrow Irradiation. (2020) (9)
- Validation of the Role of Thrombin Generation Potential by a Fully Automated System in the Identification of Breast Cancer Patients at High Risk of Disease Recurrence (2021) (9)
- Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial. (2021) (9)
- Aromatase inhibitors in premenopause: Great expectations fulfilled? (2016) (9)
- Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies (2019) (8)
- Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations (2022) (8)
- Tolerability of pemetrexed versus placebo as a maintenance therapy in advanced non-small cell lung cancer: Evidence from a large randomized study (2008) (8)
- Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma. (2015) (8)
- Efficacy and toxicity of sorafenib monotherapy in patients with advanced soft tissue sarcoma failing anthracycline-based chemotherapy. (2010) (8)
- Insuline like growth factor receptor-1 (IGFR-1), MET, and BRAF and primary resistance to cetuximab therapy in colorectal cancer patients (2008) (8)
- Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. (2020) (8)
- Controversies in the management of gastrointestinal lymphoma (1993) (8)
- Comparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-identical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide (2015) (8)
- Primary ovarian insufficiency associated with pazopanib therapy in a breast angiosarcoma patient (2019) (8)
- Treatment of advanced soft tissue sarcomas with low-dose methotrexate: a phase II trial by the European Organization of Research on Treatment for Cancer (EORTC) Soft Tissue and Bone Sarcoma Group. (1984) (8)
- Nonpeghylated liposomal doxorubicin combination regimen (R‐COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity (2020) (8)
- Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study (2014) (8)
- Pulmonary sarcomatoid carcinoma presenting both ALK rearrangement and PD-L1 high positivity (2019) (8)
- Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study (2021) (8)
- Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort (2019) (8)
- The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments (2019) (8)
- Abstract CT149: Copanlisib in patients with relapsed or refractory indolent B-cell lymphoma: Primary results of the pivotal Chronos-1 study (2017) (8)
- The Advantages of Clinical Nutrition Use in Oncologic Patients in Italy: Real World Insights (2020) (8)
- Lack of Activity of Docetaxel in Soft Tissue Sarcomas: Results of a Phase II Study of the Italian Group on Rare Tumors (1999) (8)
- Resminostat in advanced hepatocellular carcinoma (HCC): Overall survival subgroup analysis of prognostic factors in the SHELTER trial. (2013) (8)
- Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL) (2018) (7)
- 201 Treatment with gemcitabine and vinorelbine (GEMVIN) as second-line chemotherapy in pemetrexed-pretreated patients with malignant pleural mesothelioma (MPM) (2006) (7)
- Long-term, tunneled, noncuffed central venous catheter in cancer patients (Vygon): safety, efficacy, and complications (2006) (7)
- Copanlisib for the treatment of adults with relapsed follicular lymphoma (2020) (7)
- Abstract A089: Exploiting clonal evolution and liquid biopsy to overcome resistance to anti-EGFR treatment in metastatic colorectal cancer: the CHRONOS trial (2018) (7)
- Tumor and plasma biomarker analysis from the randomized controlled phase II trial (RCT) of tivantinib in second-line hepatocellular carcinoma (HCC). (2016) (7)
- Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives (2022) (7)
- Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice. (2015) (7)
- A phase II study of pemetrexed and carboplatin as front-line chemotherapy in patients with malignant pleural mesothelioma (MPM) (2005) (7)
- COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B‐CELL LYMPHOMA (CHRONOS‐1) (2017) (7)
- Clinical Relevance of Clonal Hematopoiesis in the Oldest-Old Population (2020) (7)
- Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges. (2007) (7)
- Case Report of Acute Aortic Dissection during Treatment with Capecitabine for a Late Recurrence of Breast Cancer (2010) (7)
- EFFICACY AND SAFETY IN HIGH‐RISK RELAPSED OR REFRACTORY INDOLENT FOLLICULAR LYMPHOMA PATIENTS TREATED WITH COPANLISIB (2019) (7)
- Current issues in the management of advanced Hodgkin's disease. (1990) (7)
- Avadomide (CC-122), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (2018) (7)
- Tivantinib, a New Option for Second-line Treatment of Advanced Hepatocellular Carcinoma? The Experience of Italian Centers (2015) (7)
- Lack of Response to Imatinib Mesylate as Second-Line Therapy in a Patient with C-Kit Positive Metastatic Soft Tissue Leiomyosarcoma (2005) (7)
- A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician’s Choice in a New Therapeutic Scenario (2021) (7)
- Prognostic factors and outcome of HER2+ breast cancer with CNS metastases. (2020) (7)
- Early lesions in lymphomas of germinal centre B-cell derivation: evidence and hypotheses (2012) (7)
- Peripherally Inserted Central Catheters (PICCs) Implantation in the Clinical Management of Oncohematologic Patients: Results of a Large Multicenter, Retrospective Study of the REL Group (Rete Ematologica Lombarda - Lombardy Hematologic Network, Italy) (2015) (7)
- Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. (2022) (7)
- High incidence of haemostatic interference in cancer patients treated with FOLFOX regimen and concomitant minidose of warfarin (2005) (7)
- Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer. (2019) (7)
- Rapid and Wide Immunereconstitution Obtained with HSV-TK Engineered Donor Lymphocyte Add-Backs Permits Long-Term Survival after haplo-HSCT. (2006) (7)
- High-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly versus younger lymphoma patients: a matched analysis. (2003) (7)
- Is IDH status the only factor predicting prognosis in newly diagnosed anaplastic glioma patients? Outcome evaluation and prognostic factor analysis in a single-institution large series. (2020) (7)
- B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL) (2016) (7)
- Lower Relapse and Better PFS Among Chemosensitive Patients Undergoing Allogeneic Transplantation By Haploidentical Compared With HLA-Identical DONOR: Results On A Cohort Of 94 Patients With Hodgkin’S Lymphoma (2013) (6)
- Nivolumab + ipilimumab combination therapy in patients with advanced hepatocellular carcinoma: subgroup analyses from CheckMate 040 (2020) (6)
- Solitary plasmacytoma of the duodenum (2004) (6)
- BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: A phase II study group trial of the central European Society of Anticancer-Drug Research (CESAR) (2005) (6)
- The radiologist empowerment through virtual multidisciplinary tumor boards: The commitment of oncologic care during COVID-19 pandemic (2020) (6)
- Central Nervous System Involvement in Non-Hodgkin's Lymphomas: Value of Lumbar Puncture as Initial Staging Procedure (1981) (6)
- Gastrointestinal tumors, non-colorectal (2012) (6)
- Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome (2020) (6)
- Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial (2018) (6)
- The place of chemotherapy in the management of soft tissue sarcoma: experiences of the EORTC Soft Tissue and Bone Sarcoma Group. (1989) (6)
- Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND). (2019) (6)
- 9127 The role of thymidylate synthase (TS) and excision repair cross-complementing group 1 (ERCC1) immunohistochemical expression in malignant pleural mesothelioma patients treated with pemetrexed and carboplatin (2009) (6)
- Phase II trial of NGR-hTNF and doxorubicin in relapsed small cell lung cancer (SCLC). (2011) (6)
- Randomized dose comparison phase II study of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) in patients with advanced hepatocellular carcinoma (HCC). (2013) (6)
- Results of the randomized phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy (DXCT) as first-line therapy in patients (pts) with translocation-related sarcoma (TRS). (2013) (6)
- Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas (2010) (6)
- Checkpoint inhibitors: 'raising the bar' also in brain metastases from non-small-cell lung cancer? (2018) (6)
- O126 EVALUATION OF LY2157299 MONOHYDRATE (LY), A TGF-β RECEPTOR I KINASE INHIBITOR, IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: PHASE 2 STUDY RESULTS OF SAFETY, EFFICACY AND PK/PD (2014) (6)
- Activity of regorafenib in advanced pretreated soft tissue sarcoma (2020) (6)
- P-618 ZD 1839 (Iressa) in elderly patients with progressive pretreated non small cell lung cancer (NSCLC): Results at the Istituto clinico humanitas, Rozzano, Milano (2003) (6)
- The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamide (2019) (6)
- Preliminary Results of a Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: Adjuvant Hypofractionated Whole Breast Irradiation Versus Accelerated Partial Breast Irradiation (HYPAB Trial). (2020) (6)
- Current status of the Milan trials for Hodgkin’s disease in adults (1985) (6)
- Results of a phase II clinical trial to evaluate a re-challenge of intraperitoneal catumaxomab for treatment of malignant ascites (MA) due to epithelial cancer (SECIMAS). (2013) (6)
- SAFETY AND CLINICAL ACTIVITY OF RP6530, A DUAL PI3Kδ/γ INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES: FINAL ANALYSIS OF A PHASE 1 MULTI‐CENTER STUDY (2017) (6)
- COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report (2021) (6)
- Phase I study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC). (2013) (6)
- Randomized phase II study of neoadjuvant chemotherapy in soft tissue sarcomas in adults. Protocol 62874 (1993) (6)
- Tailored Toxicity-Driven Administration of Vismodegib in Patients With Multiple or Locally Advanced Basal Cell Carcinoma: A Pilot Analysis (2020) (6)
- Chromosome 9p24.1/PD-L1/PD-L2Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade) (2016) (6)
- SORAFENIB PLUS INTERFERON-α2A IN METASTATIC RENAL CELL CARCINOMA: RESULTS FROM RAPSODY (GOIRC STUDY 0681), A RANDOMISED PROSPECTIVE PHASE II TRIAL OF TWO DIFFERENT TREATMENT SCHEDULES (2008) (6)
- Single-cell profiling defines the prognostic benefit of CD39high tissue resident memory CD8+ T cells in luminal-like breast cancer (2021) (6)
- An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab (2015) (6)
- Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients (2015) (6)
- Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial. (2022) (6)
- A double-blind placebo-controlled randomized study on the efficacy and safety of enoxaparin for the prevention of upper limb deep vein thrombosis in cancer patients with central vein catheter. (2004) (6)
- Phase IIa safety and efficacy of milciclib, a pan-cyclin dependent kinase inhibitor, in unresectable, sorafenib-refractory or -intolerant hepatocellular carcinoma patients. (2020) (5)
- Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports. (2015) (5)
- CC-122 Dosing on a Novel Intermittent Schedule Mitigates Neutropenia and Maintains Clinical Activity in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma (2015) (5)
- Phase II study of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC). (2021) (5)
- Serum levels of interleukin-2 in cancer patients: Preliminary considerations (1989) (5)
- Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question. (2019) (5)
- Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial (2021) (5)
- Therapeutic and toxicologic effects of MOPP vs ABVD when combined with RT in Hodgkin's disease (1981) (5)
- Safety of autologous fat grafting in breast cancer: a multicenter Italian study among 17 senonetwork breast units autologous fat grafting safety: a multicenter Italian retrospective study (2021) (5)
- OC-0502 Role of consolidation RT to bulky lesions of advanced Hodgkin lymphoma: results of FIL HD0801 trial (2019) (5)
- Phase Ib study of the anti-TGF-β monoclonal antibody (mAb) NIS793 combined with spartalizumab (PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid tumors. (2021) (5)
- Randomized multicenter phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy as first-line therapy in patients with translocation-related sarcoma (TRS). (2012) (5)
- Combined chemotherapy-radiotherapy approach in stages IIB, IIIA and IIIB Hodgkin's disease (1977) (5)
- Oncofid-P-B: a novel treatment for BCG unresponsive carcinoma in situ (CIS) of the bladder: Results of a prospective European Multicentre study at 15 months from treatment start. (2021) (5)
- Caspofungin for primary antifungal prophylaxis after T‐cell–replete haploidentical stem cell transplantation with post‐transplant cyclophosphamide (2019) (5)
- CC-122 Expands Activated and Memory CD4 and CD8 T Cells In Vivo and Induces T Cell Activation Ex Vivo in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma and Multiple Myeloma (2015) (5)
- Male infertility caused by the chemotherapy of Hodgkin's disease: MOPP versus ABVD. (1983) (5)
- Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study (2017) (5)
- CHECKMATE 647: A PHASE 2, OPEN‐LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA (2017) (5)
- Sinusal localization of nodal micrometastases is a prognostic factor in breast cancer. (2010) (5)
- Uncommon manifestations of common malignancies: case 1. Soft-tissue metastases from malignant pleural mesothelioma. (2004) (5)
- Mobilization of circulating progenitor cells in multiple myeloma during VCAD therapy with or without rhG-CSF. (1995) (5)
- Chemotherapy after PD‐1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics (2022) (5)
- HL-398: Five-Year Overall Survival from the CheckMate 205 Study of Nivolumab for Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) (2021) (5)
- Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2‐B3) and thymic carcinoma previously treated with chemotherapy (2021) (5)
- Review of the clinical trials activity of the Soft Tissue and Bone Sarcoma Group of the European Organization for Research and Treatment of Cancer. (1988) (5)
- Nonmyeloablative Conditioning Regimen Including Low-Dose Total Marrow/Lymphoid Irradiation Before Haploidentical Transplantation with Post-Transplantation Cyclophosphamide in Patients with Advanced Lymphoproliferative Diseases. (2021) (5)
- SAFETY RUN‐IN OF COPANLISIB IN COMBINATION WITH RITUXIMAB PLUS BENDAMUSTINE IN PATIENTS WITH RELAPSED INDOLENT NON‐HODGKIN'S LYMPHOMA (2017) (5)
- Advances in the treatment of Hodgkin's disease. (1992) (5)
- A summary of the Milan experience with multimodality therapies in patients with small cell lung cancer: attempts to improve long-term outcome. (1995) (5)
- Outcome appraisal of patients with limited brain metastases (BMs) from non small cell lung cancer (NSCLC) treated with different local therapeutic strategies: a single institute evaluation. (2017) (5)
- Retrospective analysis of central venous catheter-related thrombosis in 427 cancer patients prophylaxed with low-dose warfarin (2004) (5)
- Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation (2016) (5)
- Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications (2017) (5)
- Massive liver involvement in a patient with multiple myeloma during thalidomide treatment (2003) (5)
- Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ≥65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS. (2019) (5)
- Pemetrexed plus cisplatin (P+Cis) or pemetrexed plus carboplatin (P+Cb) for chemonaive patients (pts) with malignant pleural mesothelioma (MPM): Results of the International Expanded Access Program (EAP) (2007) (5)
- Randomized phase II study of danusertib (D) in second-line metastatic castration-resistant prostate cancer (CRPC). (2011) (5)
- Pooled Safety Analysis from Phase I and II Studies for Patients with Relapsed Indolent Non-Hodgkin's Lymphoma Treated with Intravenous Copanlisib (2017) (5)
- T and B lymphocytes and monocytes in the spleen in Hodgkin's disease: the increase in T lymphocytes in involved spleens. (1977) (5)
- CD34+ dose‐driven administration of granulocyte colony‐stimulating factor after high‐dose chemotherapy in lymphoma patients (2007) (4)
- Salvage Therapy for Hodgkin’s Lymphoma: A Review of Current Regimens and Outcomes (2020) (4)
- Sorafenib in Hepatitis C Virus-Negative Patients With Hepatocellular Carcinoma: Don't Throw the Baby Out With the Bathwater! (2017) (4)
- Prognostic factors in KRAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with biweekly cetuximab (C) plus irinotecan, fluorouracil, and leucovorin (FOLFIRI): A phase II study. (2013) (4)
- Pilot Study with Adriamycin and Ifosfamide in Small Cell Lung Cancer (1989) (4)
- Clinical staging and therapeutic results in multiple myeloma. (1983) (4)
- Chemotherapy in Advanced Soft Tissue Sarcoma — The EORTC Experience (1988) (4)
- Hypofractionated volumetric modulated arc therapy in ductal carcinoma in situ: toxicity and cosmetic outcome from a prospective series. (2018) (4)
- Trastuzumab beyond progression: a challenge to translational oncology? (2010) (4)
- "Re-irradiation for recurrent high grade glioma (HGG) patients: results of a single arm prospective phase 2 study. ". (2021) (4)
- Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: Result of a dose-intensity study (2006) (4)
- C5-01: Open-label study of pemetrexed alone or in combination with a platinum in chemonaïve patients (pts) with malignant pleural mesothelioma (MPM): Results from the International Expanded Access Program (EAP) (2007) (4)
- Gemcitabine/cisplatin in advanced transitional cell carcinoma of the urinary tract (TCC): a phase II multicenter trial (1999) (4)
- Clinical Activity and Safety of RP6530, a Dual PI3Kδ/γ Inhibitor, in Patients with Advanced Hematologic Malignancies: Final Analysis of a Phase 1 Multicenter Study (2016) (4)
- Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer. (2019) (4)
- Lung cancer in which the hypothesis of multi-step progression is confirmed by array-CGH results: A case report (2015) (4)
- A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancer (2014) (4)
- Highly-Trained Dogs ’ Olfactory System Detects Prostate Cancer in Urine Samples (2014) (4)
- FRI-499-Efficacy and hepatic safety of nivolumab treatment in patients with Child-Pugh B disease and advanced hepatocellular carcinoma in CheckMate 040 (2019) (4)
- Romidepsin-CHOEP Plus Intensification with up-Front Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: Final Results of Phase Ib PTCL13 Study of the Fondazione Italiana Linfomi (2018) (4)
- 319O The systemic pro-inflammatory response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection (2020) (4)
- Postoperative chemoradiotherapy or surgery alone for gastric cancer: the plausibility of the question and pertinence of the answer. (2010) (4)
- Cyclophosphamide 4 g/m2 Plus rhG-CSF for Mobilization of Circulating Progenitor Cells in Malignant Lymphomas (1993) (4)
- Longitudinal Assessment of Circulating Tumor Mutational Burden Using a Next-Generation Sequencing Cancer Gene Panel: A Potential Biomarker of Response to Programmed Cell Death 1 (PD-1) Blockade in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma (2019) (4)
- Dose-determination results from a phase Ib/II study of ceritinib (CER) + ribociclib (RIB) in ALK-positive (ALK+) non-small cell lung cancer (NSCLC). (2018) (4)
- Temozolomide Combined with Radiotherapy in the Treatment of Recurrent Cranial Meningioma Previously Treated with Multiple Surgical Resections and Two Sessions of Radiosurgery: A Case Report and Literature Review (2012) (4)
- Outcomes for Patients with High-Risk Relapsed or Refractory Indolent B-Cell Lymphoma Treated with Copanlisib in the CHRONOS-1 Study (2018) (4)
- Bendamustine for Relapsed/Refractory Classical Hodgkin Lymphoma After High Dose Chemotherapy and or Allogeneic Transplant: A Study of Fondazione Italiana Linfomi (FIL) (2012) (4)
- Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study. (2022) (4)
- Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma (2021) (4)
- Clinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08-01 FIL study (2019) (4)
- Copanlisib in patients with relapsed or refractory follicular lymphoma. (2017) (4)
- Low-dose warfarin prophylaxis for catheter-associated thrombosis in cancer patients. Can it be safely associated with 5-Fluorouracil-based chemotherapy? (2004) (4)
- Biomarkers in Hepatocellular Carcinoma—Letter (2012) (4)
- Endocrine Adjuvant Therapy might Impair Cardiac Autonomic Regulation in Breast Cancer Survivors (2019) (4)
- Conducting Phase I Trials During the SARS-Coronavirus-2 Outbreak: About Science and Care (2020) (4)
- Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets (2022) (4)
- Catumaxomab with and without prednisolone in patients with malignant ascites due to epithelial cancer: Results from the phase IIIb CASIMAS study. (2012) (4)
- Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) (2017) (4)
- An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes. (2019) (4)
- Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab (2021) (4)
- Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy (2020) (4)
- Phase II study of nimustine in metastatic soft tissue sarcoma. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. (1991) (4)
- Biological Characteristics and Long-term Outcomes in Node-negative Breast Cancer. (2020) (4)
- Intensified CHOP in non-Hodgkin's lymphoma: what we know and what we need to know. (1999) (3)
- P-394 Positron emission tomography with F18-fluorodeoxyglucose (FDG-PET) in malignant pleural mesothelioma (MPM): Prediction of response to chemotheraphy by quantitative assessment of standard uptake value (SUV) (2005) (3)
- Molecular Cancer Therapeutics Association of Polymorphisms in AKT 1 and EGFR with Clinical Outcome and Toxicity in Non – Small Cell Lung Cancer Patients Treated with Gefitinib (2010) (3)
- Treatment Perspectives in Advanced Non-Small Cell Lung Cancer (2000) (3)
- Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab (2021) (3)
- The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status - Trial in progress. (2018) (3)
- A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma. (2020) (3)
- R59ONC-2014-001: An open-label phase II study of regorafenib in patients with metastatic solid tumors who have progressed after standard therapy - RESOUND (2015) (3)
- Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature (2021) (3)
- Validation of liver-based quantitative analysis on PET for response assessment in patients with malignant pleural mesothelioma (MPM) (2014) (3)
- High relapse rate after a brief chemotherapy course and involved-field radiotherapy in early-stage Hodgkin lymphoma (2007) (3)
- The blurred line between the art and science of medicine☆ (2020) (3)
- Standardization of EGFR FISH in colorectal cancer: Results of an international, interlaboratory reproducibility ring study. (2011) (3)
- Single-cell profiling reveals the dynamics of cytomegalovirus-specific T cells in haploidentical hematopoietic stem cell transplantation (2021) (3)
- Updated Safety and Efficacy from the Copanlisib CHRONOS-1 Trial in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma: Low Incidence of Late-Onset Severe Toxicities (2017) (3)
- O-008Phase II study of tivantinib (ARQ 197) in combination with Cetuximab in EGFR Inhibitor-resistant, MET-High, KRAS Wild-Type (KRASwt) Metastatic Colorectal Cancer (mCRC) (2015) (3)
- Retreatment with pemetrexed-based chemotherapy (PBC) in patients with malignant pleural mesothelioma (MPM): An observational study. (2010) (3)
- Primary mediastinal B‐cell lymphoma with sclerosis: Report of 11 cases treated with intensified‐CHOP plus radiotherapy (2005) (3)
- Multicenter, prospective, case-control, observational study on the influence of venous thromboembolism on patient outcome. (2011) (3)
- 853 Ifosfamide in continuous infusion: The pharmacokinetic profile in patients with soft tissue sarcomas (1995) (3)
- Non-myeloablative conditioning regimen before T-cell replete haploidentical transplantation with post-transplant cyclophosphamide for advanced Hodgkin's and non-Hodgkin's lymphomas. (2020) (3)
- Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma (2018) (3)
- Phase II study of danusertib (D) in advanced/metastatic non-small cell lung cancers (NSCLC). (2013) (3)
- In utero stem cells transplantation after a mild immunosuppression: evidence of paternal AB0 cDNA in beta-thalassemia affected fetus. (2005) (3)
- Collection of PBSC with Fenwal CS-3000 for autografting. (1990) (3)
- Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma (2021) (3)
- Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma (2022) (3)
- Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature review. (2012) (3)
- Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors (2021) (3)
- COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry (2021) (3)
- A phase II study of regorafenib in patients with thymic epithelial tumours previously treated with chemotherapy. (2018) (3)
- Real-Life CAR-T Cell Treatment in Large B-Cell Lymphomas Indicates That Axi-Cel and Tisa-Cel Have Similar Outcomes, but Long-Term Cytopenia Is an Emerging Problem (2021) (3)
- Weekly non-pegylated liposomal doxorubicin chemotherapy in heavily pre-treated patients with metastatic breast cancer. (2013) (3)
- Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND) (2016) (3)
- A Dose Escalation Study of RP6530, a Novel Dual PI3K Delta/Gamma Inhibitor, in Patients with Relapsed/Refractory Hematologic Malignancies (2015) (3)
- Comprehensive Geriatric Assessment-Adapted Chemotherapy in Elderly Patients (>70 years) with Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL): Final Results and Long Term Follow-up. (2009) (3)
- Updated results from DIAMOND-01 (CLI24-001) trial: A phase I/II study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in acute myeloid leukemia. (2021) (3)
- Real-World Data of Nivolumab in Classical Hodgkin Lymphoma: Results from the Italian Expanded Access Programme (2017) (3)
- Ifosfamide plus Adriamycin in Advanced Soft Tissue Sarcomas (1987) (3)
- P16 Comprehensive geriatric assessment-adapted chemotherapy in elderly patients (>70 years) with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL): final results and long term follow-up (2009) (3)
- Haploidentical Stem Cell Transplantation in Lymphomas—Expectations and Pitfalls (2020) (3)
- COVID‐19 and liver cancer clinical trials: Not everything is lost (2020) (3)
- NIVOLUMAB PLUS BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EXTENDED FOLLOW‐UP FROM THE PHASE 2 CHECKMATE 436 STUDY (2021) (3)
- Phase III study of vinflunine versus docetaxel in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with a platinum containing regimen: A3-05 (2007) (3)
- Delayed childbearing and female ageing impair assisted reproductive technology outcome in survivors of male haematological cancers (2018) (3)
- Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS) (2022) (3)
- Adjuvant volumetric modulated arc therapy compared to 3d conformal radiation therapy for newly diagnosed soft tissue sarcoma of the extremities: outcome and toxicity evaluation. (2019) (3)
- Factors Affecting Outcome of Patients with Refractory/Relapsed Hodgkin’s Disease (HD) Treated with IGEV Chemotherapy (CT) and High Dose Consolidation Therapy (HDT) with Stem Cell Rescue. (2005) (3)
- Treatment of malignant lymphomas with very-high-dose CVB followed by transplantation of autologous blood stem cells collected after mobilizing chemotherapy. (1991) (3)
- What is the best option to cure patients with resistant/relapsing Hodgkin's disease? (2006) (3)
- Dual PI 3 K / ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER 3 downregulation (2016) (3)
- Measurement of Thrombin Generation Is a Positive Predictive Biomarker of V enous Thromboembolism (VTE) in Metastatic Cancer Patients Enrolled in the Hypercan Study (2015) (3)
- BIOMARKER RESULTS FROM ARQ 197-114: A PHASE 1B TRIAL EVALUATING THE c-MET INHIBITOR ARQ 197 IN CIRRHOTIC PATIENTS (PTS) WITH HEPATOCELLULAR CARCINOMA (HCC) (2010) (3)
- Pilot Study with Cisplatin, Ifosfamide, and Etoposide in Advanced Non‐Small‐Cell Lung Carcinoma (1990) (3)
- A Plasma Proteomic Signature Predicts Outcomes in a Phase 3 Study of Gemcitabine (G) + Cisplatin (C) ± Sorafenib in First Line Stage IIIB or IV NSCLC (2012) (3)
- Efficacy of Copanlisib Monotherapy in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Subset Analysis from the CHRONOS-1 Trial (2017) (3)
- Comparative therapeutic effects and morbidity of two combined treatment modalities in ps IIB-III (A+B) Hodgkin's disease (1979) (3)
- Cardiac involvement in non‐Hodgkin's lymphoma (2002) (2)
- Secondary acute myeloid leukaemia in elderly patients: Patient's fitness criteria and ELN prognostic stratification can be applied to guide treatment decisions. An analysis of 280 patients by the network rete ematologica lombarda (REL) (2018) (2)
- Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus–Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi (2022) (2)
- Phase I-Ib trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients (pts) with advanced nonsquamous NSCLC or malignant pleural mesothelioma (MPM). (2014) (2)
- Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma (2018) (2)
- Salvage Treatment with Lenalidomide and Dexamethasone in Patients with Relapsed Refractory Mantle Cell Lymphoma. (2009) (2)
- PD18-04 A PHASE 1 SAFETY STUDY OF ONCOFID-P-B ADMINISTERED FOR 12 CONSECUTIVE WEEKS IN BCG UNRESPONSIVE/INTOLERANT PATIENTS WITH BLADDER CARCINOMA IN SITU (CIS): PRELIMINARY RESULTS (2019) (2)
- Advanced colorectal liver metastases and surgery after preoperative chemotherapy: is response-based selection enough? (2011) (2)
- Immune checkpoint inhibitors in combination with radiotherapy as salvage treatment for relapsed/refractory classical Hodgkin lymphoma: A retrospective analysis in 12 patients (2021) (2)
- SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial (2021) (2)
- Long-term disease control with capecitabine in advanced breast cancer. (2017) (2)
- Extracellular Vesicles as Biomarkers of Acute Graft-vs.-Host Disease After Haploidentical Stem Cell Transplantation and Post-Transplant Cyclophosphamide (2022) (2)
- A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as fi rst-line therapy for metastatic non-small-cell lung cancer (2014) (2)
- Malignant pleural mesothelioma: The gemcitabine-vinorelbine combination in pemetrexed-pretreated patients (2008) (2)
- 5000 ORAL Long-term Outcome of HER2-positive (HER2+) Metastatic Breast Cancer (MBC) Patients (pts) Achieving Durable Complete Remission (DCR) After Trastuzumab (T)-containing Chemotherapy (CT) (2011) (2)
- The Use of FDG-PET in the Initial Staging of Patients with Follicular Lymphoma (FL). A Retrospective Study From the Fondazione Italiana Linfomi (2011) (2)
- Phase II study of fotemustine in advanced soft tissue sarcomas. A trial of the EORTC Soft Tissue and Bone Sarcoma Group. (1992) (2)
- EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients? (2007) (2)
- Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma (2021) (2)
- 1156PItalian nivolumab expanded access programme: real-world results in non-squamous non-small cell lung cancer patients (2017) (2)
- 6617 Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients (pts) with advanced hepatocellular carcinoma (HCC) (2009) (2)
- Final results of a phase II, double blind, placebo controlled, randomized trial of preoperative chemotherapy +/- gefitinib with biomarker evaluation in operable breast cancer (2006) (2)
- Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of non-small cell lung cancer patients. (2015) (2)
- A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study (2022) (2)
- A pilot analysis of headache disorders in breast cancer patients (2021) (2)
- PD12-01 ONCOFID-P-B FOR THE TREATMENT OF BCG UNRESPONSIVE CARCINOMA IN SITU (CIS) OF BLADDER (2020) (2)
- KMT2D AND TP53 MUTATIONS PREDICT POOR PFS AND OS IN MANTLE CELL LYMPHOMA RECEIVING HIGH‐DOSE THERAPY AND ASCT: THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL (2017) (2)
- Phase 1 study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC): Correlation of tumor and serum biomarker data with disease control. (2014) (2)
- 191 Pemetrexed in combination with carboplatin in elderly patients with malignant pleural mesothelioma (2006) (2)
- Is gemcitabine cost effective in cancer treatment? (2007) (2)
- Oxaliplatin (OX) and Leucovorin (L) combined with protracted-infusion Fluorouracil (F) and radiation (XRT) in locally advanced esophageal cancer (LAEC): A multicentric phase II study (2005) (2)
- Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors. (2011) (2)
- A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling (2018) (2)
- CC-122 DLBCL-001: Phase Ib Study of CC-122 Plus Rituximab in Patients with Chemo-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (2017) (2)
- The PI3K-δ Inhibitor TGR-1202 in Combination with Brentuximab Vedotin (SGN-35) Synergistically Inhibits Tubulin Polymerization and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts (2014) (2)
- 1387P Phase Ib study of LXH254 + LTT462 in patients with KRAS- or BRAF-mutant NSCLC (2020) (2)
- Phase I trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients with advanced nonsquamous non small cell lung cancer or malignant pleural mesothelioma. (2015) (2)
- Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC. (2021) (2)
- Pilot Study with Lenalidomide in Patients with POEMS Syndrome (2011) (2)
- Upregulation of Cereblon Expression By the DNA Methyltransferase Inhibitor Azacytidine Strongly Enhances Lenalidomide Cytotoxicity in Germinal Center B-Cell-like (GCB) and Activated B-Cell-like (ABC) Diffuse Large B-Cell Lymphoma (DLBCL) (2014) (2)
- Caregiver training for a therapeutic alliance in palliative home care. (2018) (2)
- T and B spleen lymphocytes in Hodgkin's disease. (1977) (2)
- Caregiver stress: Clinical evaluation and intervention strategies for caregiver burden prevention. (2017) (2)
- Short Schedule of Cisplatin and Vinorelbine: A Dose-Finding Study in Non-Small-Cell Lung Cancer (2007) (2)
- The 70-year-old newly diagnosed glioblastoma patients are older than the 65-year-old? Outcome evaluation of the two categories in a matched case control study with propensity score balancing. (2020) (2)
- Allogeneic Hematopoietic Cell Transplantation Outcomes After Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma (CA209-039 and CheckMate 205) (2017) (2)
- Treatment of Hodgkin Lymphoma Xenografts with the Novel PI3K δ/γ Inhibitor RP6530 Suppresses M2 Macrophage Polarization and Results in Potent Antitumor and Antiangiogenic Effects (2016) (2)
- The Role of Donor CMV Serostatus on Outcome after T-Cell Replete Haplo-SCT and Post-Transplant Cyclophosphamide: A Cohort Analysis on 207 Consecutive Adult Patients (2015) (2)
- Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma (2018) (2)
- NGR-hTNF and doxorubicin in relapsed small-cell lung cancer (SCLC). (2012) (2)
- Phase III study of vinflunine plus gemcitabine versus paclitaxel plus gemcitabine in the first-line treatment of anthracycline pretreated advanced breast cancer. (2014) (2)
- Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma. (2020) (2)
- Risks of molecular targeted therapies to fertility and safety during pregnancy: a review of current knowledge and future needs (2021) (2)
- Phase II trial of alternating intravenous and oral vinorelbine in combination with cisplatin in advanced non-small cell lung cancer (2007) (2)
- Fludarabine plus rituximab for untreated B-cell chronic lymphocytic leukemia. (2003) (2)
- HER2-positive breast cancer and CNS metastases: Prognostic factors and clinical outcome. (2019) (2)
- Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma (2019) (2)
- Combined approach to malignant small round blue cell neoplasms in the adult (1991) (2)
- P1.12-03 Antitumor Activity of Single Agent Lurbinectedin in Patients with Relapsed SCLC Occurring ≥30 Days After Last Platinum Dose (2019) (2)
- Prescription and Surveillance of the Acetate-Free Biofiltration Sessions: The Bicarbonate Cycle (1995) (2)
- Likelihood of metastases at diagnosis and disease-specific survival in patients with microsatellite unstable colorectal cancer (2007) (2)
- Post‐remission intensive treatment after induction chemotherapy is feasible in selected elderly patients with acute myeloid leukemia and age ≥75 years: A retrospective analysis of the Rete Ematologica Lombarda (2015) (2)
- Bendamustine in Combination with Gemcitabine and Vinorelbine (BEGEV) Is an Effective Regimen for Heavily Pretreated, Relapsed/Refractory Hodgkin Lymphoma Patients: A Multicenter, Retrospective Real-World Study (2018) (2)
- High-risk radically resected gastric cancer patients do not benefit of an adjuvant cisplatin containing regimen (2005) (2)
- 50P A phase Ib study of CC-90011, a potent, reversible, oral LSD1 inhibitor, plus etoposide and cisplatin (EP) or carboplatin (EC) in patients (Pts) with first-line (1L) extensive-stage (ES) small cell lung cancer (SCLC): Updated results (2021) (2)
- Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study (2022) (2)
- Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma (2022) (2)
- Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study (2021) (2)
- Original article: Salvage chemotherapy in Hodgkin's disease (1990) (1)
- Real-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancer. (2018) (1)
- Salvage chemotherapy (CT) in Hodgkin's disease (HD) failing to primary radiotherapy (RT): MOPP vs adriamycin-containing regimens (ADM-reg) (1982) (1)
- Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer. (2022) (1)
- Checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients? (2020) (1)
- ASCO-Abstracts (2004) (1)
- Synergistic Induction of Cell Death in Hodgkin Lymphoma Cells By the Novel PI3K Inhibitor RP6530 Combined with Brentuximab Vedotin (SGN-35) through Inhibition of Tumor Angiogenesis (2015) (1)
- Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments (2012) (1)
- Treated with Pemetrexed / Carboplatin PatientsGroup-1 as Predictors of Responsiveness in Mesothelioma Thymidylate Synthase and Excision Repair Cross-Complementing (2011) (1)
- Catumaxomab versus catumaxomab plus prednisolone in patients with malignant ascites due to epithelial cancer: results from the CASIMAS study (2012) (1)
- Mobilization of Hematopoietic Stem Cells by a Bendamustine-Containing Regimen in Hodgkin's Lymphoma (2012) (1)
- Treatment of malignant pleural mesothelioma: current status and future directions (2011) (1)
- Immunotherapeutic early-phase clinical trials and malignant gliomas: A single-center experience and comprehensive immunophenotyping of circulating leukocytes (2021) (1)
- Phase II study of ifosfamide + adriamycin in advanced soft tissue sarcoma in adults. A preliminary analysis. (1986) (1)
- NON‐SMALL‐CELL LUNG CANCER PATIENTS UNSUITABLE FOR FIRST‐LINE CHEMOTHERAPY: A NEW CATEGORY OF PATIENTS FOR CLINICAL STUDIES? (2005) (1)
- Off-label drug use in home palliative care: A non-evidence-based established practice. (2017) (1)
- Expression of folate pathway regulators and pemetrexed (pem) activity in patients (pts) with advanced non-small cell lung cancer (NSCLC). (2012) (1)
- 9007 ORAL Phase II Study of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker, in Patients With EGFR FISH-positive Advanced NSCLC (2011) (1)
- Vinorelbine (V) in pemetrexed-pretreated patients (PTS) with malignant pleural mesothelioma (MPM). (2010) (1)
- 693PNAB-PACLITAXEL (NAB-P) PLUS GEMCITABINE (GEM) VS GEM ALONE FOR PATIENTS (PTS) WITH METASTATIC PANCREATIC CANCER (PC): SUBGROUP ANALYSES OF THE MPACT TRIAL BASED ON THE PRESENCE OF LIVER METASTASES (LMS) AND NUMBER OF METASTATIC SITES. (2014) (1)
- Serum thrombospondin-1 (TSP-1), vascular endothelial growth factor (VEGF), VEGF receptor-2 (VEGFR-2), and basic-fibroblast growth factor (b-FGF) as predictive factors for sorafenib plus interferon-alfa-2a (IFN) in metastatic renal cell carcinoma (MRCC): Biologic results from the randomized phase II (2010) (1)
- P3.02c-096 Use of Nivolumab in Elderly Patients with Advanced Squamous NSCLC: Results from the Italian Expanded Access Programme (EAP): Topic: IT Clinical (2017) (1)
- The PI3K/ERK Dual Inhibitor AEZS-136 Induces ROS-Dependent Necroptotic Cell Death and Exerts Potent Antitumor Effects In NOD/SCID Mice With Hodgkin Lymphoma Cell Line Xenografts (2013) (1)
- Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Followed By Autologous Stem Cell Transplantation Produce a 3-Year Progression-Free Survival Of 75% In Heavily Pre-Treated Hodgkin and Non-Hodgkin Lymphoma (2013) (1)
- Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution. (2017) (1)
- Malignant pleural mesothelioma (MPM) in elderly patients: A multicenter survey. (2012) (1)
- 6616 Serial alpha-fetoprotein evaluation and survival in hepatocellular carcinoma patients treated with sorafenib (2009) (1)
- 415 poster ANATOMY DRIVEN OPTIMISATION OF GEOMETRICAL PARAMETERS IN MULTI-ARC AND MULTI-ISOCENTRES VOLUMETRIC MODULATED ARC THERAPY TECHNIQUE FOR TOTAL MARROW IRRADIATION (2011) (1)
- Thrombin generation predicts for early recurrence in breast cancer patients undergoing post-surgical adjuvant therapy: results from the HYPERCAN study. (2018) (1)
- Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer (2022) (1)
- Erratum to checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients? (2020) (1)
- TGFb expression as predictor of outcome in EGFR wild type (WT) metastatic non-small cell lung cancer (NSCLC) patients (PTS) treated with EGFR tyrosine kinase inhibitors (TKIs). (2012) (1)
- The PI3K-δ Inhibitor TGR-1202 In Combination With Brentuximab Vedotin (SGN-35) Synergistically Induces G2/M Phase Arrest and Cell Death Via Inhibition Of Tubulin Polymerization In Hodgkin Lymphoma Cell Lines (2013) (1)
- Four cycles of ABVD followed by involved field irradiation (IF-RT) is the treatment of choice for early-stage Hodgkin's disease (HD): 5-year results of a randomized trial (1997) (1)
- Circulating stem cell autograft in malignant lymphomas. (1990) (1)
- 870 poster SIMULTANEOUS INTEGRATED BOOST WITH VOLUMETRIC INTENSITY MODULATED RADIOTHERAPY(RAPID ARC) IN THE RADICAL TREATMENT OF 51 ADVANCED HEAD AND NECK CANCER PATIENTS: A PRELIMINARY REPORT. (2011) (1)
- Remarkable Clinical Efficacy, Stem Cell Mobilization Activity and Good Toxicity Profile of the Novel Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine) Used As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma (2015) (1)
- Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9) (2021) (1)
- An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers (2016) (1)
- Haploidentical Allogeneic Hematopoietic Cell Transplantation for Mantle Cell Lymphoma Using Post-Transplantation Cyclophosphamide Graft-Versus-Host Disease Prophylaxis (2018) (1)
- The early breast cancer (EBC) biological characteristics from NEMESI, an Italian retrospective, observational study. (2010) (1)
- Hypercoagulation Screening As a Marker of Thrombosis and Poor Disease Prognosis in Cancer Patients: The Hypercan Prospective Study (2014) (1)
- FIRST REPORT OF THE REAL‐LIFE PROSPECTIVE OBSERVATIONAL STUDY “CAR‐T CELL IN DIFFUSE LARGE B‐CELL AND PRIMARY MEDIASTINAL LYMPHOMAS” OF THE ITALIAN SOCIETY OF HEMATOLOGY (2021) (1)
- 18F-FDG-PET (PET) and contrast-enhanced CT-scan (CT) in the evaluation of liver metastases from colorectal cancer after chemotherapy (2005) (1)
- T-Replete Haploidentical Allogeneic Transplantation Using Post-Transplantation Cyclophosphamide in Advanced Acute Myeloid Leukemia and Myelodysplastic Syndromes (2016) (1)
- Phase II study of weekly administration of vinorelbine in heavily pretreated Hodgkin's disease (1993) (1)
- Highly specialized Breast Centers did not experience delay of care during COVID-19 pandemic in Italy: the Senonetwork experience (2022) (1)
- Abstract 1662: Association of EGFR and ABCG2 polymorphisms with gefitinib toxicity in non-small cell lung cancer patients (2010) (1)
- P4-09-27: Can We Predict the Benefit of the 70-Gene Signature in the Choice of Adjuvant Systemic Treatment for ER Positive, HER2 Negative Tumors in Daily Practice? A Single Institution Experience. (2011) (1)
- Liver injury by immune checkpoint inhibitors in patients with hepatocellular carcinoma. (2019) (1)
- Driver Somatic Mutations and Transplantation Decision Making in Patients with Myelodysplastic Syndrome (2016) (1)
- The psychological acceptability of follow up in a group of sarcoma patients (1993) (1)
- Circulating Tumor DNA Integrated with Interim [18F]FDG PET Is Highly Effective in Predicting Outcome of Relapsed/Refractory Classical Hodgkin Lymphoma Treated with the Begev Regimen (2021) (1)
- Risk Factors for early CMV reactivation and Impact of early CMV reactivation on Clinical Outcomes after T Cell-replete Haploidentical Transplantation with Post-transplant Cyclophosphamide. (2021) (1)
- Phase II study of ifosfamide + adriamycin in advanced soft tissue sarcoma in adults (2004) (1)
- Early restaging positron emission tomography with 18F-fluorodeoxyglucose in aggressive non-Hodgkin's lymphomas: is it too easy to be true? (2003) (1)
- Different toxicity profile of sorafenib across various types of cancer. (2010) (1)
- Bendamustine in Combination with Gemcitabine and Vinorelbine (BEGEV) is an Effective Regimen for Heavily Pretreated, Relapsed or Refractory Hodgkin Lymphoma Patients: A Retrospective Study: HL‐238 (2018) (1)
- Towards the most intensive group CHOP regimen for high-grade non-Hodgkin's lymphomas (NHL) (1999) (1)
- LBA-08 SCREENING OF BRCA2 MUTATED MEN FOR DETECTION OF PROSTATE CANCER: PRELIMINARY RESULTS FROM A NATIONAL HIGH VOLUME CANCER CENTRE (2019) (1)
- Rituximab in thrombotic microangiopathy (2007) (1)
- Severe Cytokine Release Syndrome Is a Fatal Complication after PBSC, but Not after BM Haploidentical Transplantation with Post-Transplant Cyclophosphamide (2017) (1)
- Second neoplasms in Hodgkin's disease (HD): Progress report (1985) (1)
- A17Correlation of metabolic information on 18F-FDG PET with the tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) candidate to upfront surgery (2016) (1)
- Non-Hodgkin's lymphoma (NHL) in elderly patients (pts): Patient-tailored treatment according to a comprehensive geriatric evaluation (2004) (1)
- Pretransplatation PET as Major Prognostic Discriminant in IGEV (ifosfamide, gemcitabine, vinorelbine and prednisone) Treated Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL). (2009) (1)
- Nivolumab in disadvantaged subgroups of metastatic non-small-cell lung cancer patients: a single-institution experience. (2019) (1)
- From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds (2022) (1)
- Satellite DNA analysis shows stability of donor hematopoiesis following allogeneic transplantation of peripheral blood stem cells. (2000) (1)
- A phase II multicentric trial of fotemustine (FTM) in patients (pts) with recurrent/progressive glioblastoma after radiotherapy plus concomitant and/or adjuvant temozolomide: A GICNO (Gruppo Italiano Cooperativo di Neuro-Oncologia) study (2008) (1)
- Combined modality therapy for primary gastro-intestinal non-Hodgkin's lymphoma (GI-NHL) (1993) (1)
- Tacrolimus (FK) Compared to Cyclosporine a (CyA) after Haploidentical T Cell Replete Stem Cell Transplantation (Haplo-SCT) with Post-Infusion Cyclophosphamide: A Retrospective Analysis (2014) (1)
- Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas. (2009) (1)
- PS1241 CHECKPOINT INHIBITOR TREATMENT BEFORE HAPLOIDENTICAL TRANSPLATATION IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA (HL) PATIENTS IS ASSOCIATED WITH HIGHER PFS WITHOUT INCREASED TOXICITIES (2019) (1)
- ONC-2012-001: A single-arm phase II study of tivantinib (ARQ 197) plus cetuximab in EGFR inhibitor-resistant MET high patients (pts) with locally advanced or metastatic colorectal cancer (CRC) with wild-type KRAS. (2014) (1)
- Never too old to fight breast cancer (2018) (1)
- Tamoxifene (TAM) and primary breast cancer in old women (1990) (1)
- Lack of carboplatin activity in malignant lymphomas. (1996) (1)
- 2132 POSTER Economic impact of adding capecitabine (X) to docetaxel (T) and trastuzumab (H) as first-line therapy for HER2-positive advanced or metastatic breast cancer (2007) (1)
- New technology and changing parameters of leukapheresis for blood cell transplantation. (1999) (1)
- A new human cell line, PDSS-26, from poorly differentiated synovial sarcoma, with unique chromosomal anomalies. (2003) (1)
- Biomarker analyses and association with clinical outcomes in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib with or without erlotinib in the phase III SEARCH trial. (2014) (1)
- Thrombin Generation and D-Dimer for Prediction of Disease Progression and Mortality in Patients with Metastatic Gastrointestinal Cancer (2022) (1)
- P-527 Results of a dose-finding study with short-schedule cisplatin (P) and vinorelbine (V) in non-small cell lung cancer (NSCLC): An attempt to improve feasibility and compliance (2003) (1)
- Phase II study of tivantinib (ARQ 197) and cetuximab in patients with EGFR inhibitor-resistant, MET-High, KRAS wild-type (KRASwt) metastatic colorectal cancer (mCRC). (2017) (1)
- FluCyD combination in low-grade lymphomas: An active regimen for selected patients (2004) (1)
- Developing an adolescent and young adult (AYA) cancer program in an Italian adult high-volume cancer center. (2019) (1)
- Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation (2020) (1)
- Advances in drug treatments for mesothelioma (2022) (1)
- Oncofid-P-B for the treatment of BCG unresponsive carcinoma in situ (CIS) of bladder: Results of European multicenter phase I study at the end of 12- consecutive weeks intensive course. (2020) (1)
- Low-Dose Total Marrow/Total Lymphoid Irradiation (TMI/TLI) Instead of TBI Induce Full Donor Chimerism Before T-Replete Haploidentical Transplantation (2013) (1)
- Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach (2014) (1)
- SOX2 and FGFR1 gene copy number in surgically resected non-small cell lung cancer (NSCLC). (2012) (1)
- ITALIAN STANDARDIZATION OF BCR-ABL RQ-PCR AND QUALITY CONTROL METHODS: AN OVERVIEW OF FIRST 4 YEARS RESULTS (2010) (1)
- OC-1a: A prospective study of hemostatic biomarkers to predict early recurrence in high-risk breast cancer women undergoing post-surgical adjuvant systemic therapy (2017) (1)
- Diagnosis and Treatment of Hodgkin’s Lymphoma (2013) (1)
- A Case of Pulmonary Sarcoidosis during First-Line Targeted Therapy with Dabrafenib Plus Trametinib in BRAF V600E-Mutated Metastatic Melanoma (2022) (1)
- 520 Preliminary biomarker and pharmacodynamic (PD) activity of the TGFβ inhibitor SAR439459, alone or in combination with cemiplimab, in a phase 1 clinical study in patients with advanced solid tumors (2021) (1)
- 9430 Efficacy and toxicity of sorafenib in patients with advanced soft tissue sarcoma failing anthracycline-based chemotherapy (2009) (1)
- Is Anti-Müllerian Hormone a Marker of Ovarian Reserve in Young Breast Cancer Patients Receiving a GnRH Analog during Chemotherapy? (2021) (1)
- INTERLEUKIN-16 AND THROMBOPOIETIN : NEW TOOLS FOR THE IN VITRO GENERATION OF DENDRITIC CELLS ? running headline : dendritic cells generation and IL-16 † (2004) (1)
- Abstract CT154: Isatuximab (Isa) plus atezolizumab (Atezo) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label multicenter study (2021) (1)
- Operable Breast Cancer: preliminary results of a phase II, double blind, placebo controlled, randomized trial of preoperative chemotherapy +/- gefitinib with biomarkers evaluation (2005) (1)
- A Phase 1b, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma: CC-122-DLBCL-001 (2016) (1)
- Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study (2020) (1)
- MO01.08 Phase 2 Basket Trial of Lurbinectedin in Second-line SCLC: Characteristics and Outcomes in Treatment Responders (2021) (1)
- Outcome prediction in hepatocellular carcinoma (HCC): Comparison of alphafetoprotein (AFP) response and conventional radiologic criteria during sorafenib treatment. (2010) (1)
- Serial analysis of FDG PET scans for early response evaluation in malignant pleural mesothelioma (2009) (1)
- Combined regimen of cisplatin (CDDP), adriamycin (ADM) and a-2b interferon (IFN) in the treatment of advanced malignant pleural mesothelioma (MPM): A phase II multicenter trial of the Italian Group on Rare Tumors and Italian Lung Cancer Task Force (FONICAP) (2000) (1)
- Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with hepatocellular carcinoma (HCC). (2016) (0)
- Feasibility of combination of cisplatin (CDDP) and gemcitabine (GEM) in non-small cell lung cancer and other solid tumors: analysis of dose-intensity (DI) and compliance of four different schedules (2001) (0)
- 6556 POSTER Prognostic role of standard uptake value (SUV) on positron emission tomography with 18F-fluorodeoxyglucose (FDG-PET) in malignant pleural mesothelioma (MPM) (2007) (0)
- PD-1 Inhibitors May Restore Chemo-sensitivity in Relapsed/Refractory Classical Hodgkin Lymphoma (2019) (0)
- Quality of life of adult cancer survivors enrolled in Humanitas Research Hospital’s survivorship care model (2022) (0)
- Gemcitabine a s a S ingle A gent i n t he T reatment o f R elapsed or R efractory A ggressive N on-Hodgkin's L ymphoma (1999) (0)
- Prognostic factors and disease course in patients enrolled onto clinical trials of second-line therapy for hepatocellular carcinoma. (2019) (0)
- Screening of BRCA2 mutated men for detection of prostate cancer: Preliminary results from a national high volume cancer center. (2019) (0)
- ACCURACY AND PRECISION OF RESULTS AFTER IMPLEMENTATION OF INTERNATIONALSCALE TO EVALUATE MINIMAL RESIDUAL DISEASE IN CHRONIC MYELOID LEUKEMIAPATIENTS COORDINATED ON BEHALF OF GIMEMA-CML WP (2009) (0)
- 6021 Efficacy of chemoradiotherapy for the treatment of locally advanced squamous cell carcinoma of the rectum (2009) (0)
- 782 Clinical significance of soluble II-2 receptors (S-IL-2R) in hodgkin’s disease (HD) (1995) (0)
- ATIM-28. A PHASE 1A/1B, MULTI-CENTER, OPEN-LABEL DOSE FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF THE PLEIOTROPIC PATHWAY MODIFIER CC-122 ADMINISTERED ORALLY TO PATIENTS WITH GLIOBLASTOMA MULTIFORME (GBM) AND OTHER BRAIN TUMORS (2016) (0)
- 1247 POSTER Phase I, Pharmacokinetics (PK), Pharmacodynamic (PD) Study of Lapatinib (L) in Combination With Sorafenib (S) in Patients With Advanced Refractory Solid Tumours (2011) (0)
- EP-1121: Newly diagnoses grade III glioma patients: evaluation of factors conditioning outcome (2017) (0)
- Chapter 14 – NON-HODGKIN'S LYMPHOMAS: MILAN STUDIES (1985) (0)
- Magnetic resonance staging of hodgkin disease (HD) and non-hodgkin lymphoma (NHL) (1990) (0)
- High Dose Chemotherapy (HDC) and Non Frozen ABMT in Refractory Hodgkin’s Disease (HD) (1985) (0)
- Antibacterial prophylaxis in patients with cancer and neutropenia. (2006) (0)
- Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin’s lymphoma. Assessment of risk of toxicity and secondary cancer induction (2020) (0)
- Chapter 10 – HODGKIN'S DISEASE: AN OVERVIEW AND ABVD STUDIES IN MILAN (1985) (0)
- Analysis of NTRK1 gene fusion incidence in an unselected cohort of non-small cell lung cancer patients. (2014) (0)
- Autologous Transplantation Followed by Reduced-Intensity Allogeneic Transplantation Is Feasible in Patients with High-Risk Non-Hodgkin's Lymphoma (2011) (0)
- Evaluation of Charlson comorbidity index as predictor of survival in stage II-III colorectal cancer patients treated with surgery and neoadjuvant/adjuvant chemotherapy: A single Institution observational study (2016) (0)
- S1601 NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: EFFICACY AND SAFETY RESULTS FROM THE PHASE 2 CHECKMATE 436 STUDY (2019) (0)
- A model for delivering survivorship care: Integrating the oncology and the primary care setting-An Italian experience. (2016) (0)
- Efficacy and Feasibility of DA-EPOCH-R in Aggressive B-Cell Lymphoma: A Real Life Single-Center Analysis (2019) (0)
- Maintenance of quality of life (QoL) and general health state in patients with malignant ascites during treatment with the trifunctional antibody catumaxomab: results from the phase III b CASIMAS trial (2012) (0)
- A Sex-Informed Approach to Improve Prognostication and Personalized Decision-Making Process in Myelodysplastic Syndromes. a European Study of 11.878 Patients (2020) (0)
- Non-Myeloablative Conditioning Regimen before T-Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Lymphoma (2019) (0)
- TNBC universe: A monocentric retrospective analyses of TILs and AR as prognostic markers. (2018) (0)
- Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAE\TACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: A Phase III Trial (NCT02323360) (2022) (0)
- Neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) as predictive indicators of nivolumab efficacy in metastatic non-small cell lung cancer (mNSCLC). (2018) (0)
- 93 A new staging system for small cell lung cancer (SCLC): A proposal (1995) (0)
- Higher Prevalence But Similar Infectious Profile Overtime After Haploidentical Transplantation Compared With HLA-Identical Transplantation For Hematological Diseases (2013) (0)
- Non-Hodgkin's lymphoma (NHL) in elderly patients (pts): Patient-tailored treatment according to a comprehensive geriatric evaluation. (2004) (0)
- Optimizing Anti-EGFR Strategies in Cancer Treatment (2007) (0)
- Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Hodgkin's Lymphoma (2016) (0)
- O2 Pemetrexed in combination with carboplatin in elderly patients with malignant pleural mesothelioma (MPM) (2006) (0)
- Intensified CHOP (ICHOP) +/− Rituximab in Primary Mediastinal Diffuse Large B Cell Lymphoma (PMBCL): The Role of Doxorubicin/Cyclophosphamide Dose-Intensity (2008) (0)
- Case report: Reversible punctate inflammatory foci in the corpus callosum: A novel radiological finding of CAR T-cell therapy-related neurotoxicity (2023) (0)
- A multicenter phase II basket clinical trial of lurbinectedin (PM01183) in selected advanced solid tumors. (2015) (0)
- Treatment of refractory Hodgkin’s lymphoma: a puzzle to merge (2009) (0)
- P105: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles (2022) (0)
- Intermediate-high dose sequential single agent chemotherapy combined with irradiation in advanced Hodgkin's disease (HD) (1997) (0)
- SECOND CYCLE OF CATUMAXOMAB TREATMENT IN PATIENTS WITH MALIGNANT ASCITES: RESULTS FROM THE SECIMAS STUDY (2012) (0)
- B29An open-label phase II study (RESOUND) of Regorafenib in patients with refractory solid tumors. Results of pancreatic cohort (2016) (0)
- Feasibility of Different Combinations of Chemotherapy (6 MOPP) plus Radiotherapy in Hodgkin's Disease (1979) (0)
- Clinical, pathological and molecular predictors of Fulvestrant long-term benefit in Hormone Receptor-positive / HER2 negative advanced breast cancer (2022) (0)
- Pre-Chemotherapy Levels of Hemostatic Biomarkers and Prediction of Prognosis in Newly Diagnosed Metastatic Cancer Patients from the Hypercan Study (2018) (0)
- Massive chemotherapy and non frozen bone marrow transplantation in very poor prognosis Hodgkin's disease. (1984) (0)
- Poster: HL-370 Fragmentome Profiling Reveals Distinct Molecular Subgroups of Classic Hodgkin Lymphoma (2022) (0)
- Therapeutic and Mobilizing Activity of a Vinorelbine, Ifosfamide and Cytarabine Regimen (VIHA) as Salvage Regimen In Resistant/Relapse Non Hodgkin Lymphoma (NHL) (2010) (0)
- REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION FOR THE MESUREMENT OF MINIMAL RESIDUAL DISEASE IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (2004) (0)
- Nivolumab Combined with Brentuximab Vedotin (BV) for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (R/R PMBL): Efficacy and Safety Results from the Phase 2 CheckMate 436 Study (2019) (0)
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma : Subanalyses of a phase III trial q , qq (2012) (0)
- First-line chemotherapy (CT) with pemetrexed (PEM) + cisplatin (CIS) + bevacuzimab (BEV) followed by maintenance PEM+BEV for advanced nonsquamous non-small cell lung cancer (NS-NSCLC): Final results of a single-arm phase II study. (2013) (0)
- A phase IB, multicenter, open-label study to assess the safety, tolerability, and efficacy of the pleiotropic pathway modifier CC122 administered orally to patients with advanced HCC. (2017) (0)
- OP62 Polymorphisms in AKT1 and EGFR as possible new biomarkers of clinical outcome and toxicity in non-small-cell lung cancer patients treated with gefitinib (2009) (0)
- P01.018 Mismatch repair deficiency (MMRd) in glioma patients (PTS): frequency and correlation with clinical, histological and molecular characteristics (2018) (0)
- HER2 assessment and Ki-67 labeling index in a cohort of male breast cases: The Ich Network on Cancer Research (INCaRe) experience. (2012) (0)
- Clinical and prognostic implications of sarcopenia in patients affected by locally advanced NSCLC. (2019) (0)
- Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide (2022) (0)
- Quality of life and current needs of cancer survivors enrolled in Humanitas Research Hospital's survivorship care model. (2018) (0)
- PS1237 DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVOURABLE HODGKIN LYMPHOMA (CHL): RESULTS OF A PHASE II, PROSPECTIVE, MULTI-CENTER STUDY BY FONDAZIONE ITALIANA LINFOMI (2019) (0)
- Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab (2021) (0)
- Genomic Integration of HHV-6 Mimicking Viral Reactivation after Autologous Stem Cell Transplantation (2018) (0)
- P-519 Proposals of combined approaches to thymoma: A monocentric experience (2003) (0)
- Pattern of growth of retroperitoneal sarcoma: Do they push or infiltrate adjacent organs? Analysis of a single institution series. (2010) (0)
- P-32 Feasibility of combination of cisplatin (C) and gemcitabine (G) in non-small cell lung cancer (NSCLC): Analysis of dose-intensity (DI) and compliance of four different schedules (2003) (0)
- Relation between IL-10 and IL-12 secretion in Hodgkin's disease (HD) (1997) (0)
- Clinical challenges in an unusual setting: ST-elevation in a patient suffering from graft versus host disease, between thrombosis and coronary spasm. (2021) (0)
- Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma [Corrigendum] (2016) (0)
- Retrospective analysis of an alternative immuno-score in clinical management of patients with pT2 urothelial carcinoma. (2020) (0)
- B26CROSS regimen for Oesophageal Cancer: single center experience (2016) (0)
- Current Studies at the Milan Cancer Institute with Bleomycin-Containing Regimens for Malignant Lymphomas (1982) (0)
- Phase 11-study of ifosfamide (IFS) + adriamycin (ADM) in advanced soft tissue sarcoma in adults — A preliminary analysis (1986) (0)
- P108: Integrating baseline circulating tumor DNA with interim PET improves outcome prediction in relapsed/refractory classical Hodgkin lymphoma (2022) (0)
- Abstract 2420: The dual PI3K δ/γ inhibitor RP6530 in combination with Brentuximab Vedotin (SGN-35) synergistically induces cell death via inhibition of tubulin polymerization in Hodgkin lymphoma cell lines (2015) (0)
- High-dose chemotherapy as adjuvant treatment for high-risk primary breast cancer patients. (2006) (0)
- A circulating miRNA signature to implement diagnostic imaging analysis in young early-stage breast cancer patients. (2016) (0)
- Efficacy of single administration of oral NEPA (netupitant plus palonosetron) and dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients receiving adjuvant AC-based chemotherapy – Results from GIM15-NEPA Study (2018) (0)
- Infusion of suicide gene-modified donor T cells promotes a rapid and effective immune reconstitution and provides long-term survival after haploidentical hemaopoietic cell transplantation for the cure of patients with high-risk leukemia (2008) (0)
- KEYNOTE-204: A Multicentre, Randomised, Open-Label, Phase 3 Study of Pembrolizumab versus Brentuximab Vedotin in Relapsed or Refractory Classical Hodgkin Lymphoma (2020) (0)
- 9103 POSTER Phase II Trial of NGR-hTNF and Doxorubicin in Relapsed Small Cell Lung Cancer (SCLC) (2011) (0)
- STAGING FOR CHRONIC LYMPHOCYTIC LEUKÆMIA (1979) (0)
- Prognostic role of nitrotyrosines in surgically resected non-small cell lung cancer (NSCLC). (2011) (0)
- Bone Marrow (BM) Versus Peripheral Blood Stem Cell (PBSC) For Haploidentical Transplantation With Nonmyeloblative (NMA) Conditioning Regimen and Post Infusion Cyclophosphamide (2013) (0)
- Allogeneic hematopoietic stem cell transplantation in a cohort of 314 advanced lymphoma patients. (2014) (0)
- Efficacy and safety of Copanlisib in patients with relapsed/refractory follicular lymphoma: a subset analysis of the Chronos-1 study (2017) (0)
- Complete response (CR) to ifosfamide, gemcitabine, and vinorelbine (IGEV) and outcome in relapsed/refractory Hodgkin's lymphoma (HL) patients. (2009) (0)
- 3002 ORAL Comprehensive assessment of molecular markers predicting response to cetuximab therapy in colorectal cancer (2007) (0)
- Pharmacodynamic (PD) evaluation of soluble proteins from a phase I trial of lapatinib (L) in combination with sorafenib (S). (2012) (0)
- Abstract P3-18-16: Breast conserving surgery in BRCA-mutation carriers. A single Institution experience (2022) (0)
- Trastuzumab in breast cancer. (2006) (0)
- Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial (2022) (0)
- 4264 Intravenous iron supplementation and erythropoiesis stimulating agents (ESAs): mata-analysis of randomized trials in patients with chemotherapy-induced anemia (2009) (0)
- H18Tivantinib in combination with Carboplatin and Pemetrexed as first line treatment in patients with advanced non-squamous NSCLC or Malignant Pleural Mesothelioma: results of phase I trial (2015) (0)
- availability transplantation : a retrospective study based on the time of HLA typing survival of Hodgkin lymphoma patients relapsing after autologous Allogeneic transplantation improves the overall and progression-free (2010) (0)
- Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme (2007) (0)
- Controversies and Opportunities in the Clinical Daily Use of the 21-Gene Assay for Prognostication and Prediction of Chemotherapy Benefit in HR+/HER2- Early Breast Cancer (2022) (0)
- 6146 POSTER Preclinical Study of Adoptive Immunotherapy With Natural Killer Cells in Combination With Anti-EGFR Monoclonal Antibodies and Cytokines in Metastatic Colorectal Cancer (2011) (0)
- P-619 Analysis of responses to gefitinib (ZD 1839 IressaTM) according to epidermal growth factor receptor (EGFR) expressed as staining intensity or percentage of immunoreactive cells (2003) (0)
- COPANLISIB TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (2019) (0)
- PF758 MULTI-CENTER, PHASE II STUDY ON HAPLOIDENTICAL BONE MARROW TRANSPLANTATION USING A RIC REGIMEN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH POOR PROGNOSIS LYMPHOMAS (2019) (0)
- Small round blue cell malignant tumors of soft tissues and bone in adult patients (1993) (0)
- Infusions of HSV-TK genetically modified donor lymphocytes enable a wider use of partially mismatched allogeneic transplantation by reducing infection related mortality and improving survival in high risk acute leukemia. (2006) (0)
- Prognostic factors in an open-label, nonrandomized study in chemonaive, malignant pleural mesothelioma (MPM) patients receiving pemetrexed plus cisplatin (P+Cis) or pemetrexed plus carboplatin (P+Cb) (2008) (0)
- Ox-RT study results of esophageal carcinoma. (2005) (0)
- Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 study (2017) (0)
- A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma (2018) (0)
- Abstract S01-03: The acute phase response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection as quantified by the OnCovid Inflammatory Score (2021) (0)
- EP-1409: Prospective study of hypofractionated radiotherapy for elderly patients with High Grade Glioma (2017) (0)
- The neural phenotype in invasive urothelial carcinoma patients: Alternative score detection and prognostic implication. (2020) (0)
- Abstract P5-04-07: Defining T cell dysfunctionality in breast cancer by single cell analysis: Implications for immunotherapy (2020) (0)
- SAFETY ANALYSIS OF PATIENTS WITH A MEDICAL HISTORY OF RESPIRATORY DISORDERS TREATED WITH COPANLISIB FROM THE CHRONOS‐1 STUDY IN RELAPSED OR REFRACTORY INDOLENT B‐CELL LYMPHOMA (2019) (0)
- P1-12-22: Impact on Survival of the Level of HER2/neu Gene Amplification in Patients with HER2−Positive (HER2+) Advanced Breast Cancer (AdvBrCa) Treated with Trastuzumab (H). (2011) (0)
- Better Outcome with Tandem High DOSE CHEMOTHERAPY and AUTOLOGOUS STEM CELLS TRANSPLANT IN Relapsed/Refractory HODGKIN LYMPHOMA PATIENTS Which Reached COMPLETE REMISSION AFTER Ifosfamide- Gemcitabine-Vinorelbine Scheme (IGEV). (2009) (0)
- Surrogate Predictive Biomarkers for Response to Anti-EGFR Agents: State of the Art and Challenges (2007) (0)
- P2-237: Pemetrexed as second-line treatment in advanced NSCLC patients: results on 160 patients in a multi-institutional analysis (2007) (0)
- Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi (2021) (0)
- Partecipazione a ECRIN - European Clinical Research Infrastructures Network (2011) (0)
- AB030. PS01.12. A phase II study of regorafenib in patients with thymoma and thymic carcinoma previously treated with chemotherapy (2017) (0)
- Another hospital admission through the emergency room? Looking for a fragility pattern in advanced cancer patients. (2019) (0)
- 18F-FDG PET (PET) does not improve CT scan (CT) accuracy in the evaluation of colorectal cancer liver metastases after chemotherapy. (2006) (0)
- D17Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase 3b CONSIGN trial (2016) (0)
- Positron Emission Tomography Status and Tandem High-Dose Therapy Favorably Influence Outcome of Patients with Relapsed and/or Refractory Hodgkin Lymphoma (2011) (0)
- Isolated massive meningeal progression in aggressive non Hodgkin's lymphoma. (2002) (0)
- PS1428 GCSF ALONE STEM CELL MOBILIZATION IN MULTIPLE MYELOMA PATIENTS CANDIDATES TO HIGH DOSE CHEMOTHERAPY: A MONOCENTRIC RETROSPECTIVE EXPERIENCE (2019) (0)
- In Response to Dr. Russi and Colleagues (2011) (0)
- S1597 PET-DRIVEN RADIOTHERAPY IN PATIENTS WITH LOW RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): THE DLCL10 MULTICENTER PHASE 2 TRIAL BY FONDAZIONE ITALIANA LINFOMI (FIL) (2019) (0)
- Parametrical analyses at baseline and interim PET for response assessment and outcome definition in patients affected by malignant pleural mesothelioma (MPM) (2014) (0)
- 2143 Regorafenib for previously treated metastatic colorectal cancer (mCRC): Results from 683 Italian patients treated in the open-label phase 3B CONSIGN study (2015) (0)
- Comment on: "Oncologic Safety of Autologous Fat Grafting in Breast Reconstruction". (2021) (0)
- Copanlisib (COP) in patients with relapsed or refractory indolent B-cell lymphoma: primary results of the pivotal Chronos-1 study (2017) (0)
- Bevacizumab combined with pemetrexed plus cisplatin followed by maintenance bevacizumab/pemetrexed as first-line treatment of advanced non-squamous non-small cell lung cancer: A single-arm Phase 2 study (2014) (0)
- Multicenter Phase II Study on Haploidentical Bone Marrow Transplantation Using a Reduced-Intensity Conditioning Regimen and Posttransplantation Cyclophosphamide in Patients with Poor-Prognosis Lymphomas. (2021) (0)
- Malignant pleural mesothelioma (MPM) evaluation with 11 C-methionine PET/CT before and after talc pleurodesis (2017) (0)
- Phase III study with atezolizumab versus placebo in patients with malignant pleural mesothelioma after pleurectomy/decortication (AtezoMeso study). (2022) (0)
- Hemostatic biomarkers levels for the identification of cancer patients at higher VTE risk enrolled in the HYPERCAN study (2018) (0)
- Acceptability of follow-up visits (FU) in long term survivors from Hodgkin's disease (HD) (1997) (0)
- The behavior of colorectal liver metastases in the time frame between the end of preoperative chemotherapy and liver resection: A new selection criterion for technically resectable patients. (2017) (0)
- Thrombotic Risk Assessment in a Prospective Cohort of Newly Diagnosed Ambulatory Cancer Patients Candidate to Chemotherapy (2019) (0)
- A Thrombotic Biomarker-Based Risk Assessment Scoring Model for Disease Recurrence in Breast Cancer Patient Candidate to Systemic Chemotherapy (2019) (0)
- Incidence of hepatotoxicity in patients with hepatocellular carcinoma on treatment with immune checkpoint inhibitors: impact on outcomes and tissue biomarker analysis (2020) (0)
- Long-term follow-up (FU) of patients with durable complete response (DCR) after chemotherapy (CT) and trastuzumab (T) for HER2-altered (HER2+) metastatic breast cancer (MBC). (2012) (0)
- Early and Effective Immune-Recovery by Gene-Engineered Lymphocytes after Haploidentical Transplantation for Leukemia Abate Late Transplant Mortality (2008) (0)
- H13Vinorelbine as second or third-line therapy in pemetrexed-pretreated malignant pleural mesothelioma (MPM) patients (2015) (0)
- Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma (2015) (0)
- Rituximab in thrombotic microangiopathy. Authors' reply (2007) (0)
- Predictive impact of different exon 19 deletions in EGFR-mutant NSCLC treated with first-line TKIs. (2017) (0)
- Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib (2021) (0)
- Pemetrexed plus cisplatin (P plus CIS) or carboplatin (P plus CB) in chemonaive malignant pleural mesothelioma (MPM) patients (PTS): Results of the international expanded access program (EAP) (2007) (0)
- O-0009 Second Line Therapy in Hepatocellular Carcinoma (HCC): A Randomized Controlled Phase 2 Trial (RCT) with Tivantinib (ARQ 197) (2012) (0)
- Assessment of somatostatin receptor expression in the management of (2009) (0)
- Unresectable Locally Advanced Non-small Cell Lung Cancer: Early Clinical Experience for Large Volume Targets using Volumetric Modulated Arc Therapy (2010) (0)
- Phase II, open-label study of erlotinib (ERL) in patients with NSCLC with activating mutations of the EGFR identified on tissue samples, plasma DNA, and CTC-trigger. (2013) (0)
- Inflammation and lymphoma: therapeutic implications (2015) (0)
- Role of stereotactic body radiation therapy in the management of oligometastatic pancreatic cancer: single institution experience. (2019) (0)
- Thrombin generation (TG) and D-dimer levels for the identification of cancer patients at higher VTE risk enrolled in the HYPERCAN study. (2017) (0)
- Electrolyte abnormalities and side effects of zoledronate in patients with bone metastases (2008) (0)
- Larynx Preserving Strategy in Patients with Squamous Cell Carcinoma of the Cervical Esophagus (1993) (0)
- Role of canonical and non-canonical signaling in fibroblast to cancer-associated fibroblast transition (0)
- Surgical management of BRCA-mutation carriers: A single institution experience. (2022) (0)
- EP-1032 TOTAL MARROW IRRADIATION-TMI WITH VOLUMETRIC MODULATED ARC THERAPY- VMAT IN HEMATOLOGIC MALIGNANCIES (2012) (0)
- Author response for "Non‐peghylated liposomal doxorubicin combination regimen (R‐COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity" (2020) (0)
- Autologous Stem Cell Transplantation Followed By Allogeneic SCT Provides Promising Results in Patients with Relapsed DLBCL and Adverse Prognostic Features Compared with ASCT Alone (2015) (0)
- M1* RESISTANCE TO EGFR TKIS AND SERUM PROTEOMIC PROFILE IN NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS (2008) (0)
- P107: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data (2022) (0)
- Do irinotecan (IRI) dose reductions driven by UGT1A1*28 genotyping prevent IRI-related severe neutropenia? A real-world study. (2020) (0)
- Sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (HCC): Safety and efficacy in Child-Pugh (CP) class A and B patients. (2012) (0)
- Outcome of high-grade gliomas (HGGs) treated into immunotherapeutic early-phase clinical trials (ieCTs): A single-center experience (2019) (0)
- P05.08 High-grade gliomas and immunotherapeutic early phase clinical trials: a single-center experience (2019) (0)
- Combined systemic and intrathecal chemotherapy plus radiotherapy in testicular lymphoma: a report of two cases. (2002) (0)
- EASIX predicts non-relapse mortality after haploidentical transplantation with post-transplant cyclophosphamide (2022) (0)
- Abstract OT1-4-05: Phase I dose-escalation study of oral administration of abexinostat (S 78454, PCI-24781) given with tamoxifen 20 mg in the treatment of patients with advanced breast cancer (2013) (0)
- Phase I/II study of durvalumab (anti–PD-L1 antibody) as monotherapy and in combination in patients with lymphoma or chronic lymphocytic leukemia. (2017) (0)
- Brain 18-FDG-PET patterns in early breast cancer subtypes: Relationship with headache. (2022) (0)
- Author Correction: Single-cell profiling defines the prognostic benefit of CD39high tissue resident memory CD8+ T cells in luminal-like breast cancer (2021) (0)
- P-600 Stage IIIA(N2)-IIIB non small cell lung cancer (NSCLC):Short-schedule cisplatin and vinorelbine as induction chemotherapy (2005) (0)
- Evaluation of Interaction Between NK Cells and Colorectal Carcinoma Cells for Development of NK Cell-Based Immunotherapy in Patients with Refractory Disease (2014) (0)
- PROGNOSIS OF PATIENTS WITH RELAPSED/REFRACTORY HL TREATED WITH IGEV INDUCTION THERAPY BEFORE HDCT WITH AHSCT (2010) (0)
- Pharmacoeconomic analysis of a combination of capecitabine (X) with docetaxel (D) and trastuzumab (H) first-line in HER2- positive advanced or metastatic breast cancer (2007) (0)
- DIRECT‐ACTING ANTIVIRALS AS PRIMARY TREATMENT FOR HCV‐ASSOCIATED INDOLENT NON‐HODGKIN LYMPHOMAS: THE PROSPECTIVE BART STUDY OF THE FONDAZIONE ITALIANA LINFOMI (2021) (0)
- HER2 amplification, HER2 overexpression, and TOP2A abnormalities in gastroesophageal cancers: Do they predict responsiveness to epirubicin-based chemotherapy? (2012) (0)
- Abstract CT215: Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer (2019) (0)
- Minidose W arfarin P rophylaxis f or C atheter-Associa ted Thrombosis i n C ancer P atients: C an I t B e S afely A ssociated With F luorouracil-Bas ed C hemotherapy? (2003) (0)
- 545 Second malignancies (SM) in esophageal cancer (EC) after combined modality treatment: Implications for follow-up and chemoprevention (1995) (0)
- Indicators of guideline-concordant care in lung cancer defined with a modified Delphi method and piloted in a cohort of over 5,800 cases (2020) (0)
- ASO Visual Abstract: Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1-2 Breast Cancer Patients Presenting 1-2 Metastatic Sentinel Lymph Nodes: The Multicenter Randomized Clinical Trial SINODAR-ONE (2022) (0)
- 886MO Health-related quality of life (HRQoL) from KEYNOTE-204: A phase III, randomized, open-label study of pembrolizumab (pembro) vs brentuximab vedotin (BV) in relapsed or refractory classical Hodgkin lymphoma (R/R cHL) (2020) (0)
- 6062 NGR-hTNF, a vascular targeting agent (VTA), administered as single agent in patients (pts) with colorectal cancer (CRC) failing standard regimens: a phase II study (2009) (0)
- 2039 Extension of radiotherapy (involved field vs subtotal nodal) after short-term chemotherapy in early-stage Hodgkin's disease (ESHD) (1995) (0)
- 531 A Phase 1b multi-tumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors: results of the triple-negative breast cancer, ovarian cancer, and endometrial cancer cohorts (2021) (0)
- Platinum and Pemetrexed Combination in Advanced Solid Tumors (2010) (0)
- ABCL-454: CheckMate 436: Extended Follow-Up from the Phase 2 Study Investigating Nivolumab Plus Brentuximab Vedotin (BV) for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (R/R PMBL) (2021) (0)
- A26Detection of EGFR mutations in tissue and plasma of NSCLC Patients (2016) (0)
- A randomized, double-blind, placebo (Pbo)-controlled phase III study of ombrabulin plus cisplatin in patients (pts) with advanced-stage soft-tissue sarcoma after failure of anthracycline and ifosfamide chemotherapies. (2013) (0)
- Result of FDG PET Imaging After Chemotherapy +/− Immunotherapy Is a Significant and Independent Prognostic Indicator of Outcome for Patients with Follicular Lymphoma: Survey From a Single Institution (2011) (0)
- Likelihood of metastates at diagnosis and survival of patient with microsatellite unstable colorectal cancer (2007) (0)
- SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry (2023) (0)
- The level of HER2/neu gene amplification as predictive factor in patients with metastatic breast cancer treated with a trastuzumab-based therapy (2008) (0)
- The current status and future perspectives of the multicenter randomized clinical trial SINODAR-ONE (2023) (0)
- Phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) trial of NGR-hTNF given at high doses in patients with refractory solid tumors. (2012) (0)
- Reply to Y. Pointreau et al (2012) (0)
- Nurses and health care assistants: Evaluation of attitude towards the care of patients who are terminally ill with cancer. (2018) (0)
- Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment (2022) (0)
- Letter to the Editor (2003) (0)
- Clinical outcome of EGFR-mutant NSCLC patients continuing TKIs beyond progression in combination with local ablative radiotherapy. (2017) (0)
- D29Prognostic impact of comorbidity in stage II-III colorectal cancer (CRC) patients treated with surgery and neoadjuvant/adjuvant chemotherapy: a single Institution observational study (2016) (0)
- Abstract 4711: The PI3K-δ inhibitor TGR-1202 in combination with Brentuximab Vedotin (SGN-35) synergistically induces G2/M phase arrest and cell death via inhibition of tubulin polymerization in Hodgkin lymphoma cell lines (2014) (0)
- Allogeneic Stem Cell Transplantation (Allo-SCT) after Treatment with Programmed Cell Death-1 (PD-1) Checkpoint Inhibitors for Relapsed/Refractory Classic Hodgkin Lymphoma (R/R cHL) Is Associated with an Unprecedented Low Relapse Rate (2018) (0)
- Nomograms predicting local and distant recurrence and disease-specific mortality for R0/R1 soft tissue sarcomas of the extremities (2022) (0)
- Thrombin generation for prediction of early cancer recurrence in breast cancer patients undergoing post-surgical adjuvant therapy: data from the prospective HYPERCAN study. (2017) (0)
- Quality of life in patients with malignant ascites during catumaxomab treatment: Results from the CASIMAS trial. (2012) (0)
- P-4 Preliminary results of an intensified 3-day schedule of cisplatin (P) and vinorelbine (V) as induction treatment in prognostically unfavorable locally advanced non-small-cell lung cancer (LA-NSCLC) (2003) (0)
- [Results of chemotherapy of soft tissue sarcoma in adults]. (1984) (0)
- Factors Predicting Outcome after Allogeneic Stem Cell Transplantation in Primary Refractory Acute Myeloid Leukemia: A Retrospective Analysis of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO) (2014) (0)
- Haploidentical stem cell transplantation (Haplo-HSCT) with nonmyeloablative conditioning regimen (NMAC) and postinfusion cyclophosphamide in advanced non-Hodgkin lymphoma (NHL) patients. (2014) (0)
- Array Comparative Genomic Hybridization analysis of resected thymomas on paraffin embedded material (2009) (0)
- Late intensification (LI) after induction chemotherapy (ICT) for stage IIIB small cell lung cancer (SCLC) (1993) (0)
- Immune-related adverse events and clinical outcomes in unresectable hepatocellular carcinoma: a single-institute restrospective analysis (2022) (0)
- The Role of Pemetrexed in the Pharmacotherapy of Malignant Pleural Mesothelioma (2010) (0)
- Remission and toxicity after different sequential chemotherapy (MOPP), radiotherapy (RT) programs in Hodgkin disease (1977) (0)
- Disadvantaged subgroups of metastatic non-small cell lung cancer (mNSCLC) patients treated with nivolumab. (2018) (0)
- 398 Chemotherapy (CT) with radiotherapy (RT): Larynx preservation strategy in cervical squamous cell carcinoma of the esophagus (CSCCE) (1995) (0)
- Thrombin Generation and D-Dimer Significantly Predict for Early Disease Progression and Mortality in Patients with Gastrointestinal Cancer (2020) (0)
- Gemcitabine i n t he T reatment o f R efractory H odgkin's Disease: R esults o f a M ulticenter P hase I I S tudy (2000) (0)
- 6622 POSTER Chemokine receptors CXCR4 and CX3CR1 in non-small cell lung cancer (NSCLC): pattern of expression and correlation with brain metastases (BM) (2007) (0)
- Abstract 701: The acute phase response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection as quantified by the OnCovid Inflammatory Score (2021) (0)
- Oxaliplatin (OX) and leucovorin (L) combined with proctrated-infusion fluorouracil (F) and radiation (XRT) in locally advanced esophageal cancer (LAEC): a phase II multicenter study (2005) (0)
- First-in-human (FIH) phase I study of the highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ) inhibitor IOA-244 in patients with advanced cancer: Safety, activity, pharmacokinetic (PK), and pharmacodynamic (PD) results. (2022) (0)
- Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis (2017) (0)
- Correction to: The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of pet-guided treatments (2020) (0)
- Feasibility of an intensive combined approach in advanced Hodgkin's disease (HD) (1993) (0)
- FIVE-YEAR SURVIVAL AND DURABILITY RESULTS OF THE BEGEV REGIMEN FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: PF470 (2019) (0)
- CMV-Seropositive Recipients Are at Higher Risk of CMV Reactivation and NRM after Haploidentical-SCT with PT-Cy (2019) (0)
- Use of pemetrexed with or without platin in malignant pleural mesothelioma in Italy (2008) (0)
- Phase II study with Docetaxel (Taxotere) as second line treatment of advanced soft tissues sarcomas in adult (1997) (0)
- Low-Dose Total Marrow Lymphoid Irradiation (TMLI) for Donor Chimerism Before T-Replete Haploidentical Transplantation. (2016) (0)
- Peripheral blood stem cell autograft in lymphomas (1990) (0)
- Budget impact of bi-monthly use of Cetuximab in patients diagnosed with mCRC (2019) (0)
- Phase I study of NGR-hTNF administered at high doses in refractory patients with solid tumors. (2010) (0)
- P09.36 A new therapeutic strategy for newly diagnosed glioblastoma patients: hypofractionated stereotactic radiation therapy (HSRT) delivered in 15 fractions respect to standard fractionation in 30 fractions, with concomitant temozolomide chemotherapy - A phase II study (2017) (0)
- B11Prognostic significance of the neutrophil-to-lymphocyte ratio in patients with advanced hepatocellular carcinoma: the ARQ197-215 study (2016) (0)
- A model for delivering survivorship care: Integrating the oncology and the primary care setting: Follow-up of the first cohort of patients. (2017) (0)
- Changes in shedding of soluble tumor necrosis factor receptors (sR1/R2) and in dynamic MRI as early predictors of outcome with NGR-hTNF. (2013) (0)
- Impact of pre-emptive use of tocilizumab on CAR-T-cell outcomes in non-Hodgkin lymphoma. (2023) (0)
- Clinical Impact of Q-RT-PCR Monitoring of Minimal Residual Disease in Newly Diagnosed Adult Patients with BCR-ABL+ Acute Lymphoblastic Leukemia Receiving Imatinib Mesylate Alone as a Post-Consolidation Treatment According to the Italian GIMEMA LAL 0201/A Protocol. (2004) (0)
- Peripheral T-cell lymphoma (PTCL): The milan cancer institute experience (1993) (0)
- Gemcitabine/epirubicin/paclitaxel as primary chemotherapy in stage II-IIIA operable breast cancer: final results of a multicenter Italian study (2004) (0)
- HER2 positive breast cancer with central nervous system metastases: Pathological features and clinical outcome (2016) (0)
- Clinical Implications of TP53 Mutations and p53 Dysfunction in Patients with Myelodysplastic Syndrome (MDS). a Study from the Italian MDS Clinical Network (2017) (0)
- Oral ZD1839 (iressa) in non-small cell lung cancer (NSCLC): preliminary results from a series of patients at the Istituto Clinico Humanitas, Rozzano-Milano (2001) (0)
- Five-Year Survival and Durability Results of the Phase 2 Trial Using the Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine)As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Classic Hodgkin Lymphoma (2018) (0)
- Neo-adjuvant chemotherapy in adult soft tissue sarcoma. EORTC Protocol 62847 (1997) (0)
- Critical evaluation of the role of oxaliplatin- and irinotecan-based regimens as first-line chemotherapy in advanced colorectal cancer (CRC). (2006) (0)
- Metachronous Testicular Metastases from Merkel Cell Carcinoma (MCC): A Case Report and Literature Review (2022) (0)
- Combination chemotherapy with Cisplatin (CDDP) and Adriamycin (ADM) plus immunotherapy with interferon (IFN) alfa-2b in malignant pleural mesothelioma (MPM): results of a phase II trial of the Italian Group on Rare Tumors (GITR) and Italian Lung Cancer Task Force (FONICAP) (1999) (0)
- Abstract 5041: Thymidylate synthase (TS) in malignant pleural mesothelioma (MPM): Correlation with clinical outcome and pharmacological role in the synergistic interaction of vandetanib with pemetrexed/carboplatin combination (2011) (0)
- P08.44 Phase II study of hypofractionated radiation therapy with concomitant and adjuvant temozolomide following surgical resection for patients with newly diagnosed glioblastoma: preliminary evaluation (2016) (0)
- It was hard enough: the spectre of COVID-19 on the management of sarcoma patients. (2021) (0)
- HEALTH‐RELATED QUALITY OF LIFE AMONG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL) IN A PHASE 3 STUDY OF PEMBROLIZUMAB VERSUS BRENTUXIMAB VEDOTIN (2021) (0)
- Platinum (CDDP) plus etoposide (VP 16) in the treatment of refractory solid tumors of children and adolescents (1982) (0)
- P14.17 What is the optimal therapeutic strategy for limited brain metastases (BMs) from non small cell lung cancer (NSCLC)? Prognostic factors conditioning brain control and patients outcome. (2017) (0)
- Long-term follow-up of patients (pts) with relapsed or refractory (r/r) follicular lymphoma (FL) treated with copanlisib. (2019) (0)
- 504PDTHREE OR SIX MONTHS OF ADJUVANT CHEMOTHERAPY FOR COLON CANCER: COMPLIANCE AND SAFETY OF THE PHASE III ITALIAN TOSCA TRIAL. (2014) (0)
- Patient (pt) selection for immunotherapeutic early-phase clinical trials (ieCTs): A single phase I unit experience (2019) (0)
- Clinical Relevance of Clonal Hematopoiesis in the Oldest-Old Population: Analysis of the "Health and Anemia" Study (2018) (0)
- In vitro preclinical study results for a phase I adoptive immunotherapy trial using cetuximab with allogeneic NK cells in KRAS oncogene-mutated metastatic colorectal cancer patients. (2010) (0)
- In the last decade, alternative one-stage approaches, including ultrasound-guidedhepatectomy, 7 whichdoesnotrequireportalveinem- bolization, have been developed. In this respect, our recent article 8 dis- (2011) (0)
- The switching phenotype and intratumor plasticity in carcinoma of the bladder: A mono-institutional analysis of 211 muscle-invasive carcinoma patients with clinical considerations for therapy (2021) (0)
- A Novel Gene Expression Classifier Enriches for Single Agent Clinical Activity of CC-122, a Cereblon Modulator, Administered Orally to Relapsed or Refractory Diffuse Large B-Cell Lymphoma Subjects: Results from the Phase I CC-122-ST-001 Study (2017) (0)
- Re: Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients: Sympathetic nervous system activity on breast cancer: the story of migraine. (2021) (0)
- Malignant fibrous histiocytoma of bone: Combined chemotherapy and surgery (1991) (0)
- High-grade gliomas (HGGs) and immunotherapeutic early-phase clinical trials (ieCTs): A single-center experience. (2019) (0)
- Prognostic value of the neutrophil-to-lymphocyte ratio in advanced hepatocellular carcinoma: An exploratory analysis from the ARQ197-215 study (2016) (0)
- Feasibility and Efficacy of Tandem Autologous-Allogeneic Transplantation in a Cohort of 111 Patients Affected By High-Risk Hodgkin's and Non-Hodgkin's Lymphoma (2014) (0)
- A monocentric retrospective analysis of TILs and AR as hints for prognosis definition in TNBC. (2018) (0)
- In Vitro Preclinical Study Results for a Phase I Adoptive Immunotherapy Trial Using Cetuximab in Association with Allogeneic NK Cell Infusion in KRAS Oncogene Mutated Metastatic Colorectal Cancer Patients. (2009) (0)
- MO01.09 Phase 2 Basket Trial of Lurbinectedin in Small-Cell Lung Cancer (SCLC): Analysis of Efficacy by Baseline Characteristics (2021) (0)
- Checkpoint Inhibition Before Haploidentical Stem Cell Transplantation in Relapsed or Refractory Hodgkin Lymphoma (Hl) Patients is Associated with Higher PFS without Increased Toxicities (2019) (0)
- Role of pathologic response after primary chemoradiotherapy and esophagectomy for predicted T3–4 N0-1 M0 squamous carcinoma of the thoracic esophagus (1991) (0)
- Total Marrow Irradiation: A Clinical Evaluation of a Volumetric Modulated Arc Therapy Technique (2010) (0)
- HL-370 Fragmentóme Profiling Reveals Distinct Molecular Subgroups of Classic Hodgkin Lymphoma. (2022) (0)
- 570 Cabozantinib plus atezolizumab in advanced head and neck cancer previously treated with platinum-containing chemotherapy: Results from cohort 17 of the COSMIC-021 study (2022) (0)
- Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study (2022) (0)
- EP-1168: Concurrent chemo-radiotherapy in locally advanced NSCLC: Toxicity and clinical outcomes using VMAT (rapid arc) (2014) (0)
- R05Off-label drugs use in home care: a non evidence-based established practice (2016) (0)
- developmental therapeutics 438 O PHASE II ACTIVITY OF THE HSP 90 INHIBITOR AUY 922 IN PATIENTS WITH ALK-REARRANGED ( ALK + ) OR EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER ( NSCLC ) (2012) (0)
- Prospective randomized trial in the treatment of early stage hodgkin's disease (ESHD) using involved field radiation therapy (IFRT) vs. subtotal nodal irradiation (STNI) after a short chemotherapy (CT) course (2001) (0)
- Prognostic value of the immune-related transcriptome in biliary tract cancers (2016) (0)
- PS1246 GRAFT SOURCE AND PRE-TRANSPLANT DISEASE STATUS ARE THE MAIN VARIABLES AFFECTING THE OUTCOME OF T CELL-REPLETE HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR HODGKIN LYMPHOMA (2019) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Armando Santoro?
Armando Santoro is affiliated with the following schools:
